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 Preface 
These documents have been produced by the Swedish Criteria Group for Occupational 
Exposure Limits, the members of which are presented on the next page. The Criteria 
Group is responsible for assessing the available data that might be used as a scientific 
basis for the occupational exposure limits set by the Swedish Work Environment 
Authority. It is not the mandate of the Criteria Group to propose exposure limits, but  
to provide the best possible assessments of dose-effect and dose-response relationships 
and to determine the critical effect of occupational exposure. 
 The work of the Criteria Group is documented in consensus reports, which  
are brief critical summaries of scientific studies on chemically defined substances  
or complex mixtures. The consensus reports are often based on more comprehensive 
criteria documents (see below), and usually concentrate on studies judged to be of 
particular relevance to determining occupational exposure limits. More comprehensive 
critical reviews of the scientific literature are available in other documents. 
 Literature searches are made in various databases, including Arbline, Chemical 
abstracts, Cheminfo, Medline, Nioshtic, RTECS and Toxline. Information is also drawn 
from existing criteria documents, such as those from the Nordic Expert Group (NEG), 
WHO, EU, NIOSH in the U.S., and DECOS in the Netherlands. In some cases the 
Criteria Group produces its own criteria document with a comprehensive review of  
the literature on a particular substance. 
 As a rule, the consensus reports make reference only to studies published in 
scientific journals with a peer review system. This rule may be set aside in exceptional 
cases, provided the original data is available and fully reported. Exceptions may also  
be made for chemical-physical data and information on occurrence and exposure levels, 
and for information from handbooks or documents such as reports from NIOSH and the 
Environmental Protection Agency (EPA) in the U.S. 
 A draft of the consensus report is written in the secretariat of the Criteria Group 
or by scientists appointed by the secretariat (the authors of the drafts are listed in the 
Table of Contents). After the draft has been reviewed at the Criteria Group meetings 
and accepted by the group, the consensus report is published in Swedish and English  
as the Criteria Group’s scientific basis for Swedish occupational standards. 
 This publication is the 29th in the series, and contains consensus reports approved 
by the Criteria Group from October, 2007 through June, 2008. The consensus reports in 
this and previous publications in the series are listed in the Appendix (page 67). 
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1 
Consensus Report for Creosote 
December 5, 2007 
This report is based partly on a CICAD document published in 2004 (7). The 
Criteria Group published a previous report on creosote in 1989 (27). The Swedish 
Work Environment Authority ordered an updated report focused on health risks 
from the “new” creosote products, Classes B and C, with special emphasis on  
the risks of skin exposure. This report thus deals with the creosote now used in 
European industry. 
Physical and chemical data. Uses 
CAS No.: 8001-58-9 
Mol weight: varies (complex mixture of hydrocarbons) 
Density: 1.0 – 1.17 g/cm3 at 25°C 
Boiling point/distillation interval: 200° – 400°C 
Flash point: > 66°C 
Distribution coefficient: log Poctanol/water = 1.0 
 
 
Creosote at room temperature is a dark brown to black liquid with a characteristic, 
aromatic “tarry” odor. Creosote has low solubility in water but dissolves in 
organic solvents. About 60,000 – 100,000 tons of creosote are produced annually 
in the EU. Most of it is used for impregnating wood (e.g. for use in marine 
environments). Coal tar creosote is produced from coal/coal tar by distillation 
(200° – 400°C), and consists of a large number (hundreds to thousands) of 
substances, only a few of which are present in amounts greater than 1% by weight. 
The composition of creosote varies with the origin of the coal and the distillation 
process used. Aromatic hydrocarbons, including polycyclic aromatic hydrocarbons 
(PAHs), constitute up to 90% of the product. Other components are aromatic 
compounds containing oxygen (2 to 17%, including phenols, cresol, naphthol), 
aromatic nitrogen compounds (1 to 8%, including aromatic amines), and sulfur 
compounds. The analysis of creosote is complex, and in one study, in which 85 
different substances were identified, it was also found that creosote from different 
sources can differ considerably in composition (see Table 1) (7, 29). 
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Table 1. Comparison of PAH contents in some creosote products currently or formerly 
used in industry (expressed in % by weight). 
 
Substance                 Creosote product: I1 II2 III3 IV4 
 
Biphenyl 1-4 1.5 4.4 0.1 
Naphthalene 13-18 12 0.4 0.1 
1-Methyl naphthalene 12-17 3 3 1.5 
2-Methyl naphthalene 12 8 3 0.2 
Acenaphthene 9 12 3 2 
Fluorene 7-9 5 6 5 
Phenanthrene 12-16 10 14 18 
Anthracene 2-7 1 1 1 
Fluoranthene 2-3 4.4 5 9 
Pyrene 1-5 2 3 5 
Chrysene - 0.2 0.02 0.03 
Benz[a]anthracene - 0.26 0.03 0.04 
Benzo[a]pyrene - <0.1 <0.005 <0.005 
Dibenz[a,h]anthracene - - nd nd 
Dibenzofuran 4-6 6 2 2 
Dibenzothiophene - 0.8 2 2 
Carbazole - 0.5 0.6 0.7 
 
nd = not detected. 
- = no information. 
1
 creosote previously used in Sweden for impregnating railway ties (1). 
2
 “German creosote” (29). 
3
 Class B creosote now used in industry, typical composition. 
4
 Class C creosote now used in industry, typical composition. 
 
 
Creosote, being a complex mixture of substances, has several kinds of effects 
on health. For example, it contains PAHs, which can be carcinogenic; phenols, 
which are irritating; phototoxic substances etc. Only creosotes in classes B and C 
(as defined by the European Committee for Standardization, CEN) are currently 
used in European industry. Both classes have benzo[a]pyrene (BaP) contents 
below 50 mg/kg (0.005% by weight) and phenol contents below 3% (7, 12). The 
distillation intervals for classes B and C are specified by European Standard (EN 
13991) and are described in the CICAD document (7). Class B has the distillation 
interval 235 – 400°C. According to the specifications, less than 20% by weight 
results from the distillation interval below 235°C, 40 – 60% from the distillation 
interval below 300°C and 70 – 90% from the distillation interval below 355°C. 
The higher boiling point interval means that amounts of volatile substances such 
as naphthalene and its homologues are lower than in the earlier products, and this 
may be of some importance, e.g. if naphthalene is used as an exposure indicator. 
Class C has an even lower content of volatile components: it contains nothing 
from the distillation interval below 235°C, less than 10% from the distillation 
interval below 300°C, and 65 – 95% from the distillation interval below 355°C. 
Creosote used today is not a precisely defined product. Its composition is 
approximate and varies with the origin of the coal used by the producer. Table 1 
presents the most important components in Class B and C creosotes. It is not clear 
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how the uses of these classes differ. Carcinogenicity classification of creosote has 
also varied. In 2000 the EU classified creosote with low BaP content (<0.005%  
by weight) as non-carcinogenic, but carcinogenicity classification was recently 
reintroduced on the grounds that BaP accounts for only 20% of creosote’s 
carcinogenic potency and seems to gravely underestimate the cancer risk. It is  
also important to point out that, although the new creosotes contain less of some 
PAHs, their content of others such as dibenzopyrene has not yet been examined. 
About 5,000 tons of creosote were sold in Sweden in 2005. Occupational 
exposure can occur during impregnation, transport and use of wood, repair of 
power lines, decontamination of land, and garbage handling. Extremely high 
levels of carcinogenic PAH have been found in older pressure-impregnated wood, 
which contains high levels of PAH even after several decades. Uptake is via skin 
exposure and inhalation. Time-weighted averages for creosote vapor in work 
environments have been in the interval 0.5 – 9.1 mg/m3 around impregnation  
and 0.1 – 11 mg/m3 around handling the treated wood. Particle content was in  
the range 0.2 – 46 µg/m3 (17). Concentrations of volatile PAH up to 0.9 mg/m3 
and particle-bound PAH up to 0.2 mg/m3 have been measured (stationary and 
personal monitors) during decontamination of creosote-contaminated land. 
Uptake, biotransformation, excretion 
There are no quantitative data on dermal, oral or inhalation uptake by laboratory 
animals. However, data indicate that creosote can be taken up by skin, lungs and 
digestive tract. 
Although the distribution and metabolism of creosote per se have not been 
studied, there is information on major component groups such as PAH and 
phenols. PAH is metabolized to active epoxides by the cytochrome P-450 system 
(21). Epoxides are often reactive metabolites that can bind to macromolecules 
such as nucleic acids and proteins, where they may have toxic or mutagenic 
effects. Naphthol is a metabolite of naphthalene that is found in urine and is used 
as an exposure indicator. Another metabolite detected in urine is 1-hydroxypyrene, 
formed from pyrene. Phenols are metabolized by oxidation and conjugation (20). 
Two volunteers were exposed to 100 µg creosote (39). About two drops were 
applied to an area of 200 cm2 on the lower arm, and after an hour the skin was 
washed with soap and water. Excretion of 1-hydroxypyrene in urine increased 
from background levels of about 15 – 40 pmol/hour to a maximum of about  
1000 pmol/hour after 10 to 15 hours and then declined, with a half time of about 
12 hours. Similar excretion profiles of 1-hydroxypyrene were seen in these two 
volunteers when they were exposed to 500 µg pyrene dissolved in toluene, 1 
hour/day for 5 days. In this case, some accumulation was seen over time: i.e. the 
subjects showed some increase in hydroxypyrene excretion during the week (39).  
From the above data, a total excretion of about 20 – 25 nmol 1-hydroxypyrene 
can be calculated for the two subjects exposed to creosote. Assuming total 
transformation to 1-hydroxypyrene, this corresponds to a skin uptake of of 0.1 – 
0.13 nmol pyrene/cm2/hour. 
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The importance of skin uptake is supported by the observation that use of 
protective clothing during work with creosote reduced the 1-hydroxypyrene in 
urine by 50% (4, 38). It has been estimated, on the basis of information from 
several studies, that 90% of pyrene uptake and 50 – 70% of naphthalene uptake 
occurs via the skin and that the skin is the major exposure route for people 
working with creosote (10, 38). 
Studies of 1-hydroxypyrene in urine of exposed workers suggest that 
elimination occurs in two phases, with calculated half times of one to two days  
for the initial phase and 16 days for the slower phase (22). For volunteers given  
a skin application, half time in urine was 12 hours (39). 
Biological exposure indicators 
Metabolites of naphthalene (1- and 2-naphthol) and pyrene (1-hydroxypyrene) 
have been used as exposure indicators. Amounts of 1- and 2-naphthol in urine 
correlate to the naphthalene concentration in air. Analyses of older creosote have 
shown that 8 to 20% of this creosote consisted of naphthalene, which was the 
dominant component (50 – 90% of aromatic hydrocarbons) in the air around 
creosote impregnation. Levels of 1-naphthol and 1-hydroxypyrene in urine of 
exposed workers have been measured (18), and 1-hydroxypyrene has been used as 
a biomarker for creosote exposure in several studies (10, 38, 39). The occurrence 
of 1-hydroxypyrene in urine has been shown to correlate to skin exposure, 
whereas the correlation to air concentration of pyrene was poor (7). The  
average 1-hydroxypyrene concentration in urine was 10 times higher for  
workers impregnating wood than for those handling the impregnated wood.  
Nearly all the difference could be traced to skin exposure (4, 10, 18). 
Naphthalene is/was the predominant aromatic hydrocarbon in the air around 
pressure impregnation, and air levels correlate to amounts of naphthol and 1-
hydroxypyrene excreted in urine. Levels of 1-hydroxypyrene in urine have also 
been shown to correlate to air levels of BaP in the absence of significant skin 
exposure. Naphthol was recommended by the authors as the best indicator for 
biological monitoring (37). The air concentration of naphthalene showed a good 
correlation to total PAH in air around creosote impregnation (Pearson r = 0.815) 
(33). However, the creosote used in Europe since 2000 contains very little (<1%) 
of naphthalene/naphthalene homologues, which may lessen the value of naphthol 
as a biomarker. Considering the complexity of creosote, the presently used 
exposure indicators (naphthol and 1-hydroxypyrene) are of dubious value as 
measures of exposure (7). They may nevertheless be useful in tracking the  
effects of exposure-reducing measures. 
Toxic effects 
Human data 
Ingestion of 1 – 2 grams can be lethal to a child, and 7 grams may kill an adult. 
The most obvious acute symptoms are CNS effects (dizziness, headache, loss of 
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pupillary reflexes etc.). Skin rashes are reported to be more prevalent among 
people living near impregnation plants. Several studies of occupational exposure 
have reported elevated levels of skin and eye irritation, but it is not clear what 
exposure levels yield these effects. In one study, creosote was tested according to 
OECD guidelines and classified as a skin irritant. Creosote was also classified as  
a skin irritant in another study (score 6.1) (7). Ultraviolet light has been shown to 
increase the toxicity of creosote, and photosensitization has been documented (7). 
The photoreactivity of PAHs and their formation of irritating/reactive inter-
mediates probably lie behind this effect (21). 
Skin exposure to creosote, creosote vapor, and dust containing creosote can 
result in skin irritation, reddening, eczema and hyperpigmentation. Phototoxic and 
photoallergic reactions can occur if skin is simultaneously exposed to creosote and 
sunlight: painful skin, followed by reddening and later by hyperpigmentation, has 
been reported after simultaneous exposures (2, 7, 35). 
Animal data 
The acute toxicity of creosote is moderate to low. The lowest LD50 value reported 
for oral doses to mice is 433 mg/kg. Creosote has been shown to irritate eyes and 
skin of laboratory animals (7). No NOAEL (No Observed Adverse Effect Level) 
or LOAEL (Lowest Observed Adverse Effect Level) could be derived from these 
studies. 
Genotoxicity, carcinogenicity 
Genotoxicity 
Creosote contains numerous substances classified individually as genotoxic, and 
as the composition of creosote varies so does also its genotoxic potency. Creosote 
has been shown to be mutagenic in many in vitro and in vivo assays (7). Its 
genotoxicity is similar to that of PAHs. Creosote yielded positive results in a 
micronuclei assay with mice, for example. Its ability to form DNA adducts has 
been demonstrated, most notably by formation of PAH adducts in rats and mice 
(7). For example, an extract from creosote-contaminated earth induced DNA 
adducts in several organs when it was applied to the skin of mice (32). Creosote 
has been shown to increase the bioactivation of 2,6-dinitrotoluene, and thus its 
genotoxicity, in mice (6). Ultraviolet radiation has been shown to increase the 
cytotoxicity of creosote (7). 
Elevated levels of DNA adducts have been documented in white blood cells of 
creosote-exposed workers (34). No details of exposure were given in this study. 
Human data, carcinogenicity 
The IARC has placed creosote in Group 2A (“The agent is probably carcinogenic 
to humans”) (19), and the EU has placed creosote in Category 2 (“Substances 
which should be regarded as if they are carcinogenic to man”). There are many 
older case reports of cancer in workers exposed to creosote (7). It is hard to  
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assess the available case reports and epidemiologic studies because exposure 
measurements are lacking and the composition of the creosote is not described. 
Cancer incidence in relation to creosote exposure was surveyed in Swedish and 
Norwegian men working at wood impregnation plants (23). The study included 
only workers with verified exposure. Some of the work was done outdoors. There 
was no increase in the total cancer risk (129 cases; Standardized Incidence Ratio 
(SIR) = 0.94; 95% Confidence Interval (CI): 0.78 – 1.10), although there were 
increases for lip cancer (5 observed cases; SIR = 2.5; 95% CI: 0.81 – 5.83; p = 
0.05) and skin cancer (excluding melanoma; 9 cases; SIR = 2.37; 95% CI: 1.08 – 
4.50; p = 0.02). No increase in risk was seen until after at least 20 years of 
employment. There were too few cases to allow further analysis by subgroups.  
No increase in risk for lung cancer was seen, however (13 cases; SIR = 0.79; 95% 
CI: 0.42 – 1.35). The results of the study are interpreted as indicating that working 
with creosote impregnation carries an elevated risk of skin cancer, although 
exposure to sunlight may have made some contribution as well. 
In a follow-up study of a large cohort of men employed in the French national 
electricity and gas company, 310 cases of lung cancer were identified. In an 
internal case-control study within the cohort, detailed employment information 
was matched with a job-exposure matrix for 15 different known/suspected lung 
carcinogens. A significant elevation in risk for lung cancer after creosote exposure 
was observed, even after adjustment for other exposures at the company (114 
exposed cases, 50 exposed controls; adjusted Odds Ratio (OR) for quartile with 
highest exposure = 2.14; 95% CI: 1.06 – 4.31, compared with unexposed), as well 
as a significant exposure-response correlation (28). The strong points of the study 
are the large number of exposed subjects and uniform treatment of most of the 
occupationally relevant lung carcinogens. A weakness is the lack of individual 
data on smoking. To compensate for this lack, adjustment was made for socio-
economic status (shown to be associated to smoking habits in the company). On 
the basis of this and a previous study of smoking habits in relation to the various 
exposure factors, the authors concluded that the results can not be explained by 
smoking habits. 
A recently published retrospective cohort study (40) of 2000 workers with 
potential creosote exposure at 11 pressure-impregnation plants in the United 
States reports elevated mortality due to multiple myeloma (6 cases; Standard 
Mortality Ratio (SMR) = 4.01; 95% CI: 1.47 – 8.73), and a not-significant 
increase in mortality due to lung cancer (34 cases; SMR = 1.34; 95% CI: 0.93 – 
1.87). Case-control studies within the cohort revealed no correlation to exposure 
(duration of employment, exposure category, latency time). The statistical strength 
was probably too low to support such a correlation, however – as illustrated by the 
observation that a correlation between tobacco smoking and mortality due to lung 
cancer could not be statistically proven.  
In a study based on the National Swedish Cancer Registry for 1981, 10,123 
cases of bladder cancer and 714 cases of renal pelvis cancer were identified among 
working males (36). Exposures to 50 different proven or suspected carcinogens for 
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bladder cancer were estimated using a job-exposure matrix (described in greater 
detail in Reference 31). Classifications were none, low (10 – 33%), moderate  
(33 – 66%), or high (>66%) probability of exposure, or as uncertain. Persons 
classified as exposed to creosote had a greater risk of developing bladder cancer 
than unexposed persons (48 exposed cases; Relative Risk (RR) = 1.35; 95% CI: 
1.01 – 1.79), and a not-significant increase in risk of renal pelvis cancer (6 
exposed cases; RR = 2.13; 95% CI: 0.94 – 4.8). These subjects had been 
simultaneously exposed to other carcinogens, however. When the analysis  
was limited to linemen (power, telephone/telegraph companies), classed as low-
exposure to creosote but not exposed to any other potential bladder carcinogen, 
the risk was significantly elevated for both cancer locations: RR = 1.3 (95% CI: 
1.0 – 1.8) for bladder cancer and RR = 2.6 (95% CI: 1.2 – 5.9) for renal pelvis 
cancer. The tissue (urinary epithelium) attacked by the cancer is the same for both, 
which provides some biological argument for a parallel risk increase. There is no 
information on individual smoking habits, which is a weakness of the study,  
since tobacco smoking is a proven risk factor for both these tumor locations.  
To compensate for this, the analyses were adjusted for socioeconomic status  
and degree of urbanization, both of which are correlated to smoking habits. The 
adjustments increased the risk estimates somewhat, and according to the authors 
this argues against smoking as a major contributing factor to the observed 
increases in cancer risk. 
In a case-control study of myeloma, a significant increase in risk was observed 
for creosote exposure (SIR = 4.7; 95% CI: 1.2 – 18) (15). There were only 7 cases 
and 4 controls in this study, however, and exposure classification was based on 
self-reported exposure. In a later study of myeloma (11), which also covered only 
a few cases (4 cases, 5 controls), no increase in risk was observed for creosote 
exposure. The uncertainty in the estimates was quite high, however (OR = 0.75; 
90(!)% CI: 0.21 – 2.51) and the minimum criterion for classification as exposed  
is not clear. 
In a small case-control study of lymphoma, with the same control group and 
exposure questionnaire used by Flodin et al. (15), creosote exposure was 
associated with an elevated risk for non-Hodgkin’s lymphoma (5 exposed cases,  
1 exposed control; SIR = 9.4; 90(!)% CI: 1.2 – 69) (30). In a much larger case-
control study (3) in which asphalt and creosote were combined into a single 
exposure category, no such risk for non-Hodgkin’s lymphoma was observed  
with this type of exposure (50 exposed cases; RR = 1.0; 95% CI: 0.7 – 1.5). 
The risk of childhood cancer related to parental exposure to creosote during 
pregnancy has been examined in two studies. One of them examined risk for all 
forms of cancer, acute lymphatic leukemia, and brain tumors (13). Exposure was 
classified with a job-exposure matrix. Little light could be shed on the role of 
maternal exposure as a risk factor because many women did not work while they 
were pregnant. Paternal exposure to creosote was associated with a not-significant 
increase in risk for brain tumors (5 exposed cases; OR = 3.7; 95% CI: 0.8 – 17). 
The other study examined the risk of neuroblastoma (26). Exposure classification 
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was based partly on the likelihood of a specific exposure associated with the job 
title, and partly on whether the subject reported any such exposure. There was  
an elevated risk for the father’s creosote exposure (21 exposed cases), but the  
risk was more closely associated to self-reported exposure that to job title with 
likelihood of such exposure. Since there is reason to suppose a general over-
reporting for cases in relation to controls, the authors recommend caution on 
conclusions. 
In summary, the epidemiologic studies do not present a coherent picture. 
Several studies show a possible elevation in cancer risk, but usually for different 
forms of cancer. The overall picture, including case reports, epidemiological data 
and information about the carcinogenicity of the PAH compounds in creosote, 
supports the assumption that creosote is carcinogenic to humans. 
Animal data, carcinogenicity 
Early studies in which creosote was painted onto the skin of laboratory animals 
demonstrated that creosote can be carcinogenic. In these studies there were 
elevated frequencies of skin carcinoma and papilloma as well as lung tumors, 
although no dose-response relationship could be determined (7). 
There is an unpublished study in which creosote was tested for skin cancer  
(5, cited in References 7 and 8). Two different creosotes were used. Creosote 1 
contained 10 mg BaP/kg, and creosote 2 contained 275 mg BaP/kg. A comparison 
of creosotes 1 and 2 and Class B and C (used industrially) is presented in Table 2. 
Groups of male CD-1 mice (62 per group) were given dermal applications  
of creosotes 1 and 2 dissolved in toluene (25 µl) twice a week for 78 weeks. 
Concentrations of BaP in the solution were 0, 0.2, 0.5, 1.4, or 4.1 mg/kg for 
creosote 1 and 0, 1.3, 3.8, 12.6, 37.6, or 113 mg/kg for creosote 2. Treatment of 
animals in the highest dose group (113 mg/kg) was halted after 274 days because 
of high mortality. Epithelial cancers and papillomas were induced at the site  
of application by both creosotes (Table 3). For creosote 1 there was a trend to 
increase of tumors in the two high-dose groups (1/62, 2/62). For creosote 2 there 
was a statistically significant dose-dependent increase of tumors in the three 
highest dose groups (9/62, 23/62/ 20/61). After adjustment for shortened lifespan 
and animals with lesions, the result showed a linear correlation between skin 
tumors and BaP dose. No threshold dose was indicated in the low-dose area. This 
study recorded only the occurrence of skin tumors. Calculations showed that these 
creosote samples were five times more carcinogenic than could be explained by 
their content of BaP. On the basis of this skin cancer study, the EU Scientific 
Committee on Toxicity, Ecotoxicity and the Environment (8) stated that a daily 
dose of 1 ng BaP/kg was equivalent to a lifetime increase in skin cancer risk of  
1 per 10,000. 
It is clear from the above that BaP content is not a satisfactory indicator for the 
carcinogenic potential of creosote. This conclusion is supported by studies of coal 
tar, which resembles creosote in many respects. In a 2-year cancer study, coal tar 
(from 7 different gas works) with different BaP contents (0.7, 3.6, 14 mg/kg) was 
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given orally to mice (9). In this study as well, coal tar was five times more potent 
than could be explained by the BaP content (9, 16). The composition of creosote, 
like coal tar, is complex, and any number of substances may contribute to their 
carcinogenic effects.  
Although creosote itself has not been studied for tumor-promotive effect, 
several of its components have been shown in various studies to have tumor-
promoting effects. 
 
 
Table 2. Comparison of the two creosotes (1 and 2) used in the skin cancer study 
by Buschmann et al. (5, cited in References 7 and 8) and class B and C creosotes 
used in European industry. Figures are percent by weight. 
 
Substance                Creosote type: No. 1 No. 2 Class B Class C 
 
Naphthalene 12 2 0.4 0.1 
Phenanthrene 3 12 14 18 
Anthracene 0.3 0.5 1 1 
Fluoranthene 0.4 4 5 9 
Pyrene 0.1 2 3 5 
Benz[a]anthracene 0.003 0.1 0.03 0.04 
Benzo[a]pyrene 0.001 0.03 <0.005 <0.005 
Dibenz[ah]anthracene 0.0001 0.002 nd nd 
 
 
 
Table 3. Dose-response relationships for creosote-induced skin tumors in 
mice (from Reference 5, cited in References 7 and 8). 
 
Exposure (concentration of 
BaP, mg/kg dissolved in 
toluene)*  
Total dose BaP 
(µg/mouse) 
Animals with  
skin tumors 
 
Creosote 1   
0 0 0/62 
0.2 0.5 0/62 
0.5 1.6 0/62 
1.4 4.7 1/62 
4.1 14 2/62 
Creosote 2   
0 0 0/62 
1.3 3.9 1/62 
3.8 12 3/62 
12.6 42 9/62 
37.6 128 23/62 
113 384 20/61 
 
* Applied to skin (25 µl) twice a week for 78 weeks. 
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Effects on reproduction 
No published studies on reproduction effects were found. Some unpublished 
studies are described in an assessment (draft) made at the request of the EU 
Commission (24, 25). The conclusion reported in the draft is that toxic effects on 
reproduction have been demonstrated in rats and rabbits at doses mildly toxic to 
the mothers. The main effects on fetuses/young were reduced survival and lower 
body weight. The effects were observed at relatively high oral doses (gavage) of 
creosote (> 9 mg/kg/day, 0.5% BaP). 
Creosote has been shown to compete with estrogen in a competitive ligand-
binding assay in vitro, but the effect could not be demonstrated in vivo (14). 
Dose-response/dose-effect relationships 
There are no data on which to base a dose-response or dose-effect relationship for 
humans. In a skin cancer study with mice, there was a clear, linear dose-response 
relationship (Table 3) (5, cited in References 7 and 8). Available data suggest that 
there is no lower threshold for effects. It is not clear which components in creosote 
determine its carcinogenicity. 
Conclusions 
Creosote is genotoxic and induces skin cancer in laboratory animals. Studies  
of occupationally exposed groups indicate that creosote may be carcinogenic  
to humans. There is no support in the literature for a different assessment of  
the “new” creosotes (Classes B and C). 
Creosote is irritating to eyes and skin. Skin damage may be intensified by 
sunlight (creosote is phototoxic). 
Studies with volunteers and in work environments indicate that the most 
important exposure route for creosote is via skin. 
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Consensus Report for Ethylene Glycol 
Ethylether and Ethylene Glycol 
Ethylether Acetate 
February 6, 2008 
Literature searches were made in August of 2005 and January of 2007, and some 
subsequently published material was also used. The Criteria Group published a 
previous consensus report for ethylene glycol ethylether (EGEE) and some other 
glycol ethers in 1983 (53). A consensus report for ethylene glycol methylether 
(EGME) and its acetate was published in 1999 (54). 
Chemical and physical characteristics 
Ethylene glycol ethylether (EGEE) 
CAS No.: 110-80-5 
Synonyms: ethylene glycol monoethyl ether, 
 2-ethoxy ethanol, ethoxyethanol, ethyl glycol 
Structure:  CH3-CH2-O-CH2-CH2-OH 
Mol weight: 90.12 
Density: 0.93 (20°C) 
Boiling point: 135°C 
Melting point: - 100°C 
Vapor pressure: 0.76 kPa (25°C) 
Evaporation rate: 0.41 (butyl acetate =1) 
Flash point: 43°C (closed cup) 
Saturation concentration:  7600 ppm (25°C) 
Relative vapor density: 3.1 (air =1)  
Distribution coefficient: - 0.32 
   (log Poctanol/water) 
Conversion factors:  1 ppm = 3.74 mg/m3 
   (20°C, 101 kPa) 1 mg/m3 = 0.27 ppm  
 
Ethylene glycol ethylether acetate (EGEEA) 
CAS No.: 111-15-9 
Synonyms: ethylene glycol monoethyl ether acetate, 
 2-ethoxyethyl acetate, 2-ethoxyethanol acetate, 
 ethyl glycol acetate 
Structure: CH3-CH2-O-CH2-CH2-O-CO-CH3 
Mol weight: 132.16 
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Density: 0.97 (20°C) 
Boiling point: 156°C 
Melting point: - 62°C 
Vapor pressure: 0.37 kPa (25°C) 
Evaporation rate: 0.2 (butyl acetate = 1) 
Flash point: 52°C (closed cup) 
Saturation concentration: 3700 ppm (25°C) 
Relative vapor density: 4.6 (air = 1) 
Distribution coefficient: 0.59 
   (log Poctanol/water) 
Conversion factors: 1 ppm = 5.48 mg/m3 
   (20°C, 101 kPa) 1 mg/m3 = 0.18 ppm 
 
 
EGEE and its acetate (EGEEA) at room temperature are clear, flammable  
liquids with relatively low vapor pressure and a weak odor. EGEE mixes in all 
proportions with water, ethanol and ethyl ether. EGEEA is somewhat less soluble 
in water (23 g/100 ml at 20°C) and more soluble in oil than EGEE. EGEEA mixes 
readily with aromatic hydrocarbons, ethanol, ethyl ether etc. (10, 18, 42, 44, 68, 
73). 
Occurrence, use, exposure 
Neither EGEE nor EGEEA occurs naturally (42). Both glycol ethers have been 
widely used as solvents for resins, lacquers, paints and ink. They have been used 
in combination with other solvents (e.g. in silkscreening of textiles, paper, plastic), 
in leather making, ship and aircraft painting, paint/surface coatings for vehicles 
and metal containers for food, and in manufacture of circuit boards and paints. 
Use as antifreeze in airplane fuel and as a chemical intermediate is also reported 
(8, 43, 52, 79, 92). In Sweden in 2003, EGEE was a registered ingredient  
in 21 products and EGEEA in 19 products. Neither substance was produced 
domestically. Both substances were used in paints, and EGEEA was also used  
in glue and in metal coatings (47). Neither EGEE nor EGEEA is permitted in 
consumer products, and both substances are classified by the EU as toxic to 
reproduction: Category 2 (this applies to all products containing ≥ 0.5%) (49,  
50, 51). 
Reported 8-hour averages for air concentrations of EGEEA around silkscreen 
printing have generally been <10 ppm. A Finnish study reports 8-hour averages 
ranging from 2.7 to 9.1 ppm on different weekdays, with a few 8-hour values 
approaching 40 ppm (55). A Chinese study reports 8-hour averages of 1.4 to  
16.5 ppm (overall average 7.4 ppm) in a printing department, although average 
air concentrations up to about 60 ppm had been measured there earlier (11, 58). 
Veulemans et al. (89) report in general relatively low air concentrations around 
production in a silkscreen printing business, with averages of 2.2 ppm EGEEA 
and 1.6 ppm EGEE (4-hour samples). Johanson et al. (45) also report low air 
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concentrations of EGEEA: an 8-hour average of 0.9 ppm. Other data give average 
values of 2.6 ppm for EGEEA and 0.2 ppm for EGEE around silkscreen printing 
(92). Silkscreen printing involves frequent cleaning with EGEE/EGEEA, and 
exposure via direct skin contact also occurs (55, 92). 
Eight-hour averages of up to 24 ppm (geometric mean 6.6 ppm) EGEE have 
been reported to occur around metal casting (14, 74). Averages up to 2 – 3 ppm 
EGEE/EGEEA have been reported around paint production (4, 84). Average  
air levels of about 15 ppm EGEEA (range 5.4 – 27.8 ppm) have been measured 
around airplane painting (95 – 250-minute samples) (91, 92). Group averages of  
2 – 3 ppm EGEE/EGEEA have been reported for shipyard painters, though with  
a few time-weighted averages (TWA) up to about 20 ppm (52, 79). Spray painting 
is used for both ships and airplanes, and face masks are often worn: skin uptake of 
vapor therefore probably accounts for much of the exposure (52, 91, 92). 
Uptake, biotransformation, excretion 
Both chemical structure and solubility characteristics indicate that EGEE and its 
acetate are rapidly taken up via skin, lungs and digestive tract (42). The relative 
uptake (retention) in airways was reported in one study to be about 80% when 
volunteers were exposed to 14 ppm EGEE for 4 x 15 minutes (10 minutes 
between exposures) (48). When volunteers were exposed while resting to 2.7 –  
11 ppm EGEE or 2.5 – 9 ppm EGEEA for 4 x 50 minutes (10 minutes between 
exposures), retention was reported to be about 60 – 65% for EGEE and 50 – 60% 
for EGEEA. Retention increased to about 70% when the subjects were exercising 
(equivalent to 30 or 60 W) during exposure to 5 ppm EGEE (4 x 50 min.). Similar 
results were obtained with exposure to 5 ppm EGEEA (27, 29). 
EGEE and EGEEA, especially in liquid form, are rapidly and efficiently 
absorbed by the skin, and significant skin uptake has also been demonstrated for 
EGEE in vapor form. The absorption rate for undiluted EGEE/EGEEA applied  
to human skin in vitro has in various studies been calculated to be 0.6 – 1.4 
mg/cm2/hour (6, 21, 57, 85). EGEE in water is taken up more readily than 
undiluted EGEE. For human skin in vitro, the maximum absorption rate for a 75% 
EGEE solution was 1.9 mg/cm2/hour and for a 50% solution 1.5 mg/cm2/hour 
(85). For volunteers exposed to liquid EGEE the calculated absorption rate was 
0.7 (0.4 – 1.1) mg/cm2/hour. Extrapolation to 2000 cm2 of skin (approximate area 
of both hands and lower arms) and 1 hour of exposure yielded an average skin 
uptake of 1539 mg. This is about 20 times the uptake calculated for 8 hours of 
inhalation exposure at the present Swedish exposure limit of 5 ppm. The authors 
further calculate that, with whole-body exposure to EGEE vapor, 42% of the total 
uptake is via skin (48). In vitro tests with human skin have shown that EGEE 
weakens the skin’s barrier function somewhat more than water, and EGEEA  
about as much as water (21).  
The chemical characteristics of EGEE indicate that it is distributed quite evenly 
in blood and most tissues, but has low solubility in fat tissue. EGEEA is more fat-
soluble than EGEE and thus should be distributed in fat tissue to a somewhat 
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greater extent (29, 44). EGEEA is rapidly hydrolyzed to EGEE by carboxyl 
esterases in nasal mucosa and blood, however. Hydrolysis in liver, kidneys and 
lungs has also been demonstrated for 2-alkoxy ethyl acetates such as EGEEA  
(25, 81). The 2-alkoxy ethanols, including EGEE, are substrates for alcohol 
dehydrogenase, which catalyzes transformation to aldehydes: these in turn are 
metabolized via aldehyde dehydrogenase to alkoxyacetic acids. The toxicity  
of EGEE is due to its biotransformation via ethoxy acetaldehyde (EALD) to 
ethoxyacetic acid (EAA); this is accordingly the most important metabolic path 
for EGEE. Biotransformation via microsomal oxidation to ethylene glycol is 
another metabolic path for EGEE (8, 25, 56, 61). For women with occupational 
exposure to 2 ppm EGEE 8 hours/day, or to 64 ppm 15 minutes/day (at the start  
of the workday), 5 days/week for 14 days, toxicokinetic calculations yield a 
maximum blood concentration of about 0.9 µM EAA at the end of work on  
day 11 – 12 (83). 
Metabolism via alcohol dehydrogenase can be inhibited by ethanol and pyrazole 
(8). Simultaneous exposure to common solvents such as toluene and xylene can 
also affect the metabolism of EGEE/EGEEA by reducing the formation of EAA, 
thus reducing e.g. the toxic effect on testes (13, 100). Esterification of EGEE to 
EGEEA has not been shown to affect the degree of testicular toxicity in 
experimental animals (63). 
Both EGEE and EGEEA are excreted primarily as metabolites in urine. 
Volunteers exposed to 2.7 – 11 ppm EGEE or 2.5 – 9 ppm EGEEA for about  
4 hours excreted on average 23% and 22% respectively of the absorbed dose as 
EAA in urine within 42 hours; ≤0.5% of uptake (both substances) was recovered 
in unchanged form in exhaled air. The level of EAA in urine increased with the 
dose. With exposure to 2.7, 5.4 or 11 ppm EGEE for 4 hours (resting), 3.2, 6.1  
and 8.8 mg EAA/liter (2.7, 5.1, 7.3 mg EAA/g creatinine) were measured in urine 
4 hours after exposure was ended. The corresponding exposure to 2,5, 5 or 9 ppm 
EGEEA resulted in urine excretions of 2.2, 4.0 and 6.5 mg EAA/liter (1.8, 3.3,  
5.4 mg EAA/g creatinine). Increased workload also increased urinary excretion  
of EAA. The excretion rate for EAA in urine reached a maximum 3 to 4 hours 
after exposure was ended, and the half time for elimination was determined to be 
21 – 24 hours (27, 28, 29, 30). In a later study (31), however, the authors give a 
half time of 42 hours for elimination of EAA (based on the same material). This 
study further reports a much shorter half time, about 7 hours, for EAA (free and 
conjugated) in rats (single doses of 0.5 – 100 mg EGEE/kg b.w., per os) (31). The 
long half time for EAA in humans may lead to accumulation (4, 84, 89). In a study 
of occupationally exposed workers, the half time for excretion of EAA in urine 
was calculated to be about 60 hours, with wide variation (84). 
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Table 1. Correlations between EGEE or EGEEA in air (translated to 5 ppm) and EAA in 
urine. 
 
Reference EAA 
(mg/g creatinine) 
Remarks 
 
At the end of the workweek (end of fifth workday) 
(89) 150 Field study, probable skin exposure. 
Droz  
   (see Ref. 1) 
114 Theoretical calculations based on 
Groeseneken et al. (t1/2 EAA = 42 hours), 
exposure by inhalation only, value for light 
exercise (50 W). 
(86) 100 Theoretical calculations based on a 
toxicokinetic model (data source not given), 
exposure by inhalation only. 
Hattis 1988 
   (see Ref. 1) 
68 Theoretical calculations based on 
Groeseneken et al. (t1/2 EAA = 22 hours), 
exposure by inhalation only. 
(56) 65 Field study, probable skin exposure. 
Appendix 1  48 and 61 
 
Theoretical calculations based on 
Groeseneken et al. (t1/2 EAA = 42 and 21 
hours respectively), exposure by inhalation 
only.  
Other times /times not reported 
Angerer et al. 
   (see Ref. 1) 
100 
(120 mg/l) 
Field study, probable skin exposure, value 
after two workdays. 
Vincent 1991 
   (see Ref. 1) 
34 – 50 Field study, skin exposure may have 
contributed, weekday not reported. 
Droz 
   (see Ref. 1) 
38 Theoretical calculations based on 
Groeseneken et al. (t1/2 EAA = 42 hours), 
exposure by inhalation only, value after an 8-
hour exposure (resting). 
(45) 38 Field study, probable skin exposure, weekday 
not reported. 
NIOSH 1991 
   (see Ref. 1) 
25 Theoretical calculations based on 
Groeseneken et al. (t1/2 EAA = 42 hours), 
exposure by inhalation only, value after an 8-
hour exposure. 
 
 
Biological exposure monitoring 
EAA in urine can be used as an exposure indicator for EGEE and EGEEA. Field 
studies and toxicokinetic calculations indicate that exposure to 5 ppm EGEE or 
EGEEA for a workweek (8 hours/day, 5 days/week) corresponds to 50 – 150 mg 
EAA/g creatinine in urine samples taken after the fifth workday (Table 1). Factors 
that may affect the EAA value in urine and may also explain why the correlations 
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between levels in air and urine are different in different studies include 
contribution from skin exposure, workload, time the sample was taken,  
and analysis method. 
Toxic effects 
Human data 
Effects involving the central nervous system, liver and kidneys were reported in a 
woman who accidentally drank 40 ml EGEE. She became dizzy, had chest pains 
and lost consciousness. The toxic picture included cyanosis, pulmonary edema, 
metabolic acidosis, spasms, enlarged liver and jaundice. Her urine contained 
acetone, protein and red blood cells (42, 68). 
Hematological effects of exposure were studied in 94 painters at a shipyard and 
55 controls (Table 2). When the groups were compared there were no significant 
differences in average levels of hemoglobin in blood (Hb) or total number of 
white blood cells of the PMN type (polymorphonuclear leukocytes), but 9 of  
147 subjects had Hb values below 140 g/l (anemia) and all of these were painters. 
Values for red blood cell size and hemoglobin content were normal for all 9. Five 
painters, but no controls, had low numbers of white blood cells (PMN <1800 
cells/µl), but none of these had anemia. Review of medical records (12/14) 
showed that the reductions in Hb and PMN had occurred during their employment 
as painters. Measured air concentrations (8-hour) of EGEE and EGME for the 
exposed group were reported to be ≤21.5 ppm (average 2.6) for EGEE and ≤5.6 
ppm (average 0.8) for EGME, but it was pointed out that the levels were probably 
higher most of the time. Face masks were worn by 4 of the 10 subjects with 
highest exposure. Skin uptake probably occurred and was probably quite high 
(there was also some direct skin contact). Air monitoring and product review 
indicated generally negligible benzene exposure. Of the 94 painters, 45 were 
described as lead-exposed, but all of these had blood lead levels ≤40 µg/dl  
(≤1.9 µmol/l) – most of them <20 µg/dl (<1 µmol/l). The authors concluded  
that exposure to benzene or lead could not explain the observed hematological  
effects and ascribed them to the glycol ether exposure (79, 93). 
Effects on blood profile are also reported in a cross-sectional study of shipyard 
painters exposed to solvents containing EGEEA (52). The study covered 30 men 
judged to have high exposure (Group A) and 27 men judged to have low exposure 
(Group B), as well as a control group. Subnormal numbers of white blood cells 
(<4500 cells/µl) were seen in 6/57 painters (5 from Group A) and 0/41 controls; 
only 2 of the 6 painters had values below 4000 cells/µl and these were in Group  
A. Multiple regression analysis showed that persons in Groups A and B had lower 
white blood cell counts than controls after correction for smoking and alcohol 
consumption, and that the number of white blood cells decreased with increasing 
EAA. When group averages were compared there were significantly lower values 
for number of white blood cells and granulocytes and higher values for red blood 
cell size in Group A, but no significant differences between groups in numbers of 
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thrombocytes or red blood cells, Hb values, hematocrit, or hemoglobin content in 
red blood cells. Bone marrow samples from 3 subjects with low numbers of white 
blood cells (2 in Group A, 1 in Group B) indicated hypoplastic bone marrow.  
No significant differences between exposed groups and controls were seen in  
liver function tests. Personal monitors showed air levels of EGEEA ≤18.3 ppm 
(average 3.0) for Group A (n = 18) and ≤8.1 ppm (average 1.8) for Group B (n = 
12). Nine of 18 in Group A had values >5 ppm, and most of these were spray 
painters. It was reported that face masks were worn by many of the workers  
in Group A, but skin uptake may be assumed. EAA in urine was ≤227.3 mg/g 
creatinine (average 9.2) in Group A (n = 25) and ≤15.1 mg/g creatinine (average 
0.6) in Group B (n = 26). Reported air concentrations (Group A) were up to 155 
ppm for toluene, 250 ppm for xylene, and 159 ppm for methyl isobutyl ketone 
(MIBK). No benzene or other ethylene glycol ethers were identified. Measured 
blood lead levels were <20 µg/dl (<1 µmol/l). 
A 1998 study of 12 female and 17 male silk screening workers at a factory 
where EGEEA was used as the primary solvent for cleaning/printing operations, 
and 56 persons in a low-exposure control group, reports significantly lower Hb 
and hematocrit values in the blood of the female silk screening workers than in 
female controls (Table 2), but no significant effects on other parameters (numbers 
of red and white blood cells, lymphocytes and thrombocytes, red blood cell size 
and Hb content). In the men there were no differences for any of the examined 
parameters. Negative dose-response relationships between EGEEA in air and Hb, 
hematocrit and number of red blood cells in blood were seen in regression models 
after adjustment for confounding factors (not seen for number of white blood cells 
or thrombocytes). The average air concentration of EGEEA (8-hour) was 0.07 
ppm for the low-exposure control group (n = 26) and 7.4 ppm for the more highly 
exposed group (n = 29), but there were exposure differences between men and 
women: the average for the female silk screening workers was 9.3 ppm and for the 
men 4.9 ppm. With manual printing, workers spent 8 hours at their machines 
(10/12 were women) and cleaning sometimes occurred with consequent skin 
uptake of EGEEA. These workers could also be exposed to “small amounts” of 
toluene and MIBK. No benzene or other substances known to affect blood profile 
were detected, either in the materials used or in air samples. Exposure levels of 
EGEEA had previously been much higher, but the authors believe this had 
minimal effect on their study results (58). The workers began wearing butyl rubber 
gloves the year after this study, and hematological examinations were again made 
in 2000 and 2002. These showed no significant inter-group differences for Hb  
and hematocrit in blood of the women, but there were somewhat lower values 
(especially in 2000) for both silk screening workers and controls. For men there 
was a significant difference between silk screening workers and controls for 
thrombocyte numbers in both 2000 and 2002. In a longitudinal analysis of  
workers who participated in all three examinations (silk screening workers:  
5 women, 12 men; controls: 12 women, 13 men) it was observed that Hb and 
hematocrit in blood, but not numbers of white blood cells and thrombocytes,  
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had significant correlations to exposure. Hb and related parameters increased more 
in exposed subjects (after they began wearing gloves) than in the control group, 
and the authors concluded that the primary exposure route for EGEEA was skin 
uptake rather than inhalation (11). 
Animal data 
EGEE and EGEEA have low to moderate acute toxicity. Reported LD50 values 
(dose lethal to 50% of animals) range from 3.3 to 15.2 g/kg body weight for skin 
application and from 1 to 8.1 g/kg b.w. for oral administration (rats, mice, guinea 
pigs, rabbits) (8, 42, 46). For EGEE in vapor form, an LC50 (air concentration 
lethal to 50% of animals) of 1820 ppm (7 hours) has been reported for mice,  
and 4000 ppm (4 hours) and 2000 ppm (8 hours) for rats. In experiments with 
EGEEA, it is reported that 2/6 rats died with 8 hours of exposure to 1500 ppm  
(9, 46, 95). For EGEEA, an RD50 (concentration yielding a 50% reduction in 
respiratory rate, a measure of respiratory irritation) of 719 ppm (mice) is given  
in a survey article (2). 
In an inhalation study, pregnant rats and rabbits were exposed 6 hours/day to  
50, 100, 200 or 300 ppm EGEEA: dose-dependent hematological effects were 
seen in both species (mothers) (Table 4). The rats had significantly lower Hb and 
hematocrit and lower values for number and size of red blood cells at levels ≥100 
ppm. Significantly higher numbers of white blood cells and lower numbers of 
thrombocytes were noted at air concentrations of ≥200 ppm. In the rabbits, the 
number of thrombocytes was significantly lower at ≥100 ppm and red blood cells 
were larger at 300 ppm. Rabbits exposed to 200 or 300 ppm had blood in urine. 
Poorer initial weight gain was also reported in rabbits at air levels ≥100 ppm and 
in rats at 200 ppm and higher. Rabbits had higher absolute liver weights at 300 
ppm. Higher absolute liver weights were observed in rats in all dose groups, and 
higher relative liver weights at ≥100 ppm. In this study the NOAEL for maternal 
toxicity was judged to be 50 ppm for both species (88). 
In another reproduction study, rats were exposed to 10, 50, or 250 ppm and 
rabbits to 10, 50 or 175 ppm EGEE for 6 hours/day during gestation (Table 3). 
Minor hematological effects were observed in the mother rats (lower Hb and 
hematocrit, smaller size of red blood cells) at 250 ppm, but body weight was 
unaffected. No such effects were observed in the rabbits at any dose level. In this 
study, however, there was marginally lower Hb in the mother rabbits exposed to 
400 ppm EGEEA (but not 100 ppm). Effects on body weight and food intake 
(significant at 400 ppm) were also seen (20). 
Lower Hb, hematocrit and numbers of red blood cells at 400 ppm were also 
seen in rabbits in another study. In this study, rats and rabbits were exposed to 25, 
100, or 400 ppm EGEE 6 hours/day, 5 days/week for 13 weeks. The anemia was 
apparently a result of increased destruction of red blood cells (bone marrow was 
normal). Poorer weight gain was also observed, especially at 400 ppm (also 
significant at 25 ppm, but not 100 ppm, after 13 weeks). In the rats, there were  
a few statistically significant effects on hematological and clinical-chemical 
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parameters and organ weights (including lower absolute and relative pituitary 
weights in male animals at 400 ppm), but the authors considered that they were 
unrelated to the exposure or of unclear biological significance. No treatment-
related histopathological changes were observed in either species, except for some 
effects on the testes of the rabbits (Table 3). Tear flow and nasal secretion were 
higher in all exposed groups (both species) than in controls, but were reportedly 
not dose-related. Ophthalmological examination revealed no treatment-related 
effects. The NOAEL given in this study was 100 ppm for rabbits (estimated to  
be about 50 mg/kg b.w./day; 100% uptake was also assumed) and 400 ppm for 
rats (5).  
There is a briefly described study with a few rats and rabbits, reporting normal 
Hb values and no effects on numbers of red and white blood cells with inhalation 
exposure to 200 ppm EGEEA 4 hours/day, 5 days/week for 10 months. No 
significant differences in weight gain were seen. Histological examination 
revealed several different changes in kidneys (focal tubular nephritis with clear 
hyaline and granular tubular casts) but only in male animals. There were no 
reported changes in other examined organs (brain, lungs, heart, liver, spleen, 
pancreas, bladder, adrenals, testes, ovaries) (87). 
In an older study with rats, indications of hemolysis and somewhat elevated 
proportions of immature white blood cells were reported after exposure to about 
370 ppm EGEE 7 hours/day for 5 weeks (96). In another rat study, the lowest 
concentration that yielded significant hemolysis (erythrocyte osmotic fragility test) 
in female rats immediately after 4 hours of inhalation exposure was reported to be 
125 ppm for EGEE and 62 ppm for EGEEA, and the highest concentration that 
produced no indication of this effect was 62 ppm for EGEE and 32 ppm for 
EGEEA (9). There are no further details on results with EGEE/EGEEA, but data 
from studies with exposure to ethylene glycol butylether indicate that rats and 
other rodents are more likely than humans to develop hemolysis with glycol ether 
exposure (9). An older study with dogs (only a few animals) reports a large 
increase in immature white blood cells and slight reductions in red blood cell 
numbers, hematocrit and Hb with inhalation exposure to about 800 ppm EGEE,  
7 hours/day for 12 weeks. Erythrocytes were small and changed in appearance. 
Histological examination of tissues (including liver, kidneys, lungs, spleen,  
heart) yielded no clear evidence of other exposure-related effects (97). 
In a study in which EGEE was given to dogs per os (in capsules) 7 days/week 
for 13 weeks, in doses corresponding to 47, 93 or 186 mg/kg b.w./day (50, 100  
or 200 µl/kg/day) there were dose-related reductions in Hb and hematocrit after  
5 to 13 weeks: the reported NOEL in this study was 47 mg/kg/day. In a similar  
13-week study in which rats were given the substance by gavage, the reported 
NOEL for these changes in blood profile was 93 mg/kg/day (186 mg/kg/day 
yielded possible effects on Hb and hematocrit). Minor histopathological changes 
in kidneys (dogs), iron accumulation in spleen (rats), and changes in testes of  
both species were noted with administration of 186 mg/kg /day, although no 
effects on livers were observed at this level (80). 
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Giving rats EGEE by gavage, 150 mg/kg b.w. 6 times/week for 4 weeks, 
resulted in bone marrow suppression (reduction in number of white blood cells 
and thrombocytes, lower Hb and hematocrit, lower hemoglobin content in red 
blood cells). Lower adrenal weight and lower values for plasma protein, plasma 
creatinine and alkalic phosphatases were also recorded, but there was no effect  
on aspartate amino transferase (ASAT), alanine amino transferase (ALAT), blood 
urea nitrogen or total cholesterol. Bone marrow suppression of similar severity, as 
well as reduced plasma creatinine, alkalic phosphatases and ASAT, were observed 
with administration of EGEE (150 mg/kg b.w.) in combination with toluene (250 
mg/kg) and xylene (500 mg/kg). The bone marrow toxicity of EGEE thus does  
not decline with simultaneous administration of these solvents, as is the case for 
testicular toxicity (100). 
EGEE, EGEEA and EAA were tested for immunotoxic potential in a study  
with rats. The substances were given by gavage in doses of 50 – 400 mg/kg/day 
for 2 days to rats that had been previously immunized with trinitrophenyl-
lipopolysaccharide (TNP-LPS). No significant effect on antibody response  
was observed (78).  
EGEE and EGEEA were judged to produce no significant skin irritation when 
tested on laboratory animals. When EGEE and EGEEA were tested on rabbits 
using an EEC test method (occlusion, 4 hours), both substances were judged to  
be non-irritating. In a Draize test with rabbits (occlusion, 24 hours), EGEEA was 
classed as mildly irritating to skin. Liquid EGEE splashed in the eyes has been 
reported to cause immediate pain, but judging from eye tests at various labo-
ratories the substance seems to cause only slight, temporary irritation (8, 101). 
Mutagenicity, genotoxicity 
EGEE and EGEEA, both with and without metabolic activation, are reported to  
be non-mutagenic in in vitro assays with E. coli and various strains of Salmonella 
typhimurium (8, 42, 46, 68). In one study it was also shown that the metabolites 
EALD (up to 100 µmol/plate) and EAA (up to 21 µmol/plate) were not mutagenic 
to bacteria (Salmonella typhimurium strains TA97a, TA98, TA100, TA102), either 
with or without metabolic activation (39). EGEE and EGEEA are also reported to 
yield negative results in mutagenicity tests with mammalian cells in vitro. One 
study, however, reports that EGEE after metabolic activation was weakly positive 
in a mutation test with mouse lymphoma cells (3 – 5 µl/ml) (46, 69). 
Sister chromatid exchanges (SCE) have been reported in several in vitro  
studies in which EGEE was tested on Chinese hamster ovary (CHO) cells both 
with and without metabolic activation, as well as in an in vitro study on human 
lymphocytes. Chromosome aberrations were also seen in CHO cells (only in tests 
without metabolic activation), but no increase of chromosome breaks was seen in 
human lymphocytes in vitro (46, 68). When both EGEE and its metabolites were 
tested in a large study on mammalian cells (including V79 cells) in vitro, EGEE at 
high concentrations was reported to give unclear or weakly positive results in tests 
for induction of SCE, chromosome aberrations, micronuclei and aneuploidy; it 
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was judged as not productive of chromosome breaks or morphologic trans-
formations, whereas EALD was genotoxic at lower concentrations. EALD  
yielded increases in chromosome aberrations, SCE, micronuclei and aneuploidy  
at 0.1 – 1 mM, but was negative in tests for morphological transformation. EAA 
caused no increase of chromosome aberrations or SCE, but was judged to be 
weakly positive at 10 mM in tests for micronuclei. In tests for tumor-promotive 
activity, EGEE at non-cytotoxic concentrations (55 – 166 mM) showed a dose-
dependent inhibition of intercellular communication, whereas neither EALD nor 
EAA had such an effect (22). Overall, the available data indicate a potential for 
induction of cytogenetic damage in vitro. 
There are a few in vivo tests with EGEE/EGEEA. EGEE was non-mutagenic  
in sex-linked recessive lethal tests with Drosophila (46, 60, 68). In a study in 
which mice were given a single intraperitoneal injection of EGEE, up to 3 g/kg 
b.w., or 200 mg EAA/kg b.w., no significant increase of micronuclei in bone 
marrow cells was reported (22). There is an abstract reporting no significant 
increase of micronuclei in peripheral polychromatic red blood cells of mice  
after intraperitoneal injection of EGEE in doses of 25%, 50% or 80% of the LD50 
(2589 mg/kg) (32). In another abstract, EGEEA is reported not to be clastogenic  
in vivo (micronuclei test, bone marrow cells of mice) (77). 
Cytogenetic examination of blood taken after the workshift on a Tuesday from 
19 workers exposed to various levels of glycol ethers and other solvents revealed 
no elevation in SCE or micronuclei in lymphocytes. The 12 subjects who were 
varnish production workers had the highest exposure to EGEE/EGEEA. Average 
air concentrations (personal monitors) of EGEE and EGEEA for these subjects 
were 2.9 ppm for EGEE (range <0.6 – 15.2) and 0.5 ppm for EGEEA (range <0.1 
– 3.7) on Monday (after an exposure-free weekend) and 2.1 ppm (range <0.1 – 
6.2) and 0.1 ppm (range <0.1 – 0.4) respectively on Tuesday, but there was some 
skin uptake. EAA in urine of these 12 workers was on average 53.2 (range 2.3 – 
180) mg/l before work on Monday and 53.8 (range 11.1 – 143.7) mg/l after work 
on Tuesday (84). 
Carcinogenicity 
No acceptably conducted and documented cancer studies were found in the 
literature. 
Anti-carcinogenic effect (leukemia) has been reported in laboratory  
animals with administration of EGEE. In one study, leukemia response (blood 
profile changes, effects on spleen) was observed to be lower in rats injected 
subcutaneously with leukemia cells and given daily doses of EGEE in drinking 
water (2.5 g/l, about 150 mg/kg b.w./day) for 2 months, than in a control group 
that did not receive EGEE (19). 
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Effects on reproduction 
Human data 
Some ethylene glycol ethers are toxic to spermatozoa, primarily mature 
spermatocytes. The effect was therefore considered to be reversible if exposure  
is stopped (72), although this was questioned in a subsequent study (62). 
In a study of painters at a shipyard, reduced semen quality was more common in 
the painters than in a control group; the attrition in this study was large, however 
(94). Ten of 73 painters had ≤ 20 million sperm/ml (2/40 in controls), and 4 of 
these had virtually no sperm at all (0/40 in controls). (Proportion of men with 
sperm concentrations ≤ 20 million/ml: 13,7% vs. 5%; p = 0.12.) Number of sperm 
per ejaculate was also lower in this group than in controls. There was a significant 
difference (p = 0.05) between exposed nonsmokers and nonsmokers in the control 
group (36.4% vs 15.6%; OR = 2.8). Exposure for the painters was on average 2.6 
ppm EGEE and 0.8 ppm EGME (8-hour time-weighted averages, TWA), but there 
was considerable variation, with average values up to 21.5 ppm EGEE and 5.6 
ppm EGME. Skin uptake also occurred. Further, the authors warn that their 
measurements may not be representative and that higher exposures may have 
occurred. They relate that due to job rotation there was considerable variation in  
a worker’s job (and thus exposure), and that individual exposures could not be 
assessed from either air samples or urine samples. Although the painters were 
exposed to many other substances, the authors consider that the glycol ether 
exposure may lie behind the observed effects. The painters described as exposed 
to lead had blood lead levels ≤ 40 µg/dl, in most cases < 20 µg/dl (79, 94). 
Effects were also seen in a cross-sectional study in which sperm quality was 
examined in men exposed to EGEE in connection with production of castings. 
The study participants were 37 men with potential daily exposure and 38 men  
who were not exposed. Attrition in this study was large. It was reported that use  
of EGEE had been stopped in 2 of 3 buildings two or three weeks before the 
assessment. A marginally significant reduction (p = 0.05) in number of sperm  
per ejaculate was seen in the exposed group. The proportion of men with sperm 
concentrations ≤ 20 million/ml was also higher (16.2% vs 10.5%, not significant), 
but no men were entirely without sperm. Average levels of EGEE recorded by 
personal monitors (8-hour samples, TWA) ranged from not detectable to 24 ppm 
(geometric mean 6.6 ppm). There were some analysis problems, however, and the 
authors state that the actual concentrations may have been higher. Splashing and 
spilling was reported to occur. Detectable amounts of EAA were found in nearly 
all urine samples from exposed subjects, with levels ranging from 16 to 163 mg/g 
creatinine (14, 74). Significant effects of EGEE exposure on sperm concentration 
(p = 0.034) and semen volume (p = 0.032) were seen with combined analysis (76) 
of the studies described above (74, 94). 
In a Belgian case-control study covering 1019 men with clinically diagnosed 
infertility or reduced fertility and 475 controls with normal fertility, EAA  
was detected in urine in 39 cases and 6 controls (OR = 3.11; p = 0.004), in 
concentrations ranging from 1.3 to 71 mg/l; 39 of these men had sperm 
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concentrations < 20 million/ml, and 11 had no sperm at all. Methoxyacetic acid (a 
metabolite of EGME) was identified in only 1 case and 2 controls (90). Reduced 
fertility was not reported in a cross-sectional study of 1538 men employed in 
semiconductor manufacture (a sub-study in the Semiconductor Health Study) (75). 
No effects on a number of menstruation parameters (cycle length, duration, 
flow, dysmenorrhea) were found in a study of 52 women who made LCD screens 
and who were exposed to EGEEA, when they were compared with a reference 
group (n = 55). Eight-hour records from personal monitors yielded a geometric 
mean of 0.51 ppm (range 0.15 – 3.03 ppm). Urine samples were submitted before 
and after the workshift. The average pre-shift value was 0.12 (range 0.02 – 0.88) 
mg/g creatinine, and the post-shift average was 0.16 (range 0.02 – 1.24) mg/g 
creatinine. No skin contact with EGEEA was reported to occur (12). 
Elevated frequencies of spontaneous abortions are reported in several 
epidemiologic studies of women working in the semiconductor industry in the 
United States (7, 17, 71, 82). These women were exposed to EGEE, EGEEA, 
EGME and/or other ethylene glycol ethers, and also to other types of solvents. 
There is little information on exposure levels, and none of the studies contains 
direct measurement of dermal exposure. 
The studies by Beaumont et al. (7) and Swan et al. (82) covered 14 production 
companies in the semiconductor industry (891 pregnancies) (Semiconductor 
Health Study, SHS). Air concentrations of EGEEA (time-weighted averages, full-
shift samples) were on average 0.022 ppm (highest average 0.75 ppm), but there 
was also uptake via direct skin contact with the liquid. Personal monitors showed 
air concentrations of <0.010 ppm EGME and average exposure of 0.008 ppm for 
1-methoxypropyl acetate. Cluster analysis (exposure assessment) indicated a large 
number of individuals with simultaneous exposure to xylene, n-butyl acetate  
and ethylene glycol ethers. There was reported to be a statistical correlation to 
spontaneous abortions for each of these solvents for workers in photolithography 
and etching, and the risk was seen to increase with exposure. However, there was 
a low frequency of spontaneous abortions among the few women who were 
exposed to xylene and/or n-butyl acetate but not ethylene glycol ethers, or to 
ethylene glycol ethers but not xylene or n-butyl acetate (34, 38, 82). In a small 
prospective study within the framework of the SHS, urine samples were used  
to identify pregnancies and detect subclinical abortions: 403 women (including 
controls) were followed for up to 6 months by analysis of chorionic gonadotropin 
(HCG), and 52 became pregnant. Of these, 3 were exposed to ethylene glycol 
ethers and all 3 had spontaneous abortions. Two of these three had also been 
exposed to fluoride. There was a fourth woman who had a miscarriage; she was 
not included in the prospective study but was exposed to ethylene glycol ethers 
(24). 
The study by Correa, Gray et al. (17, 26) contains a retrospective cohort  
study of employed women (561 pregnancies) and wives of employed men  
(589 pregnancies) at two electronics factories. Significantly elevated risk for 
spontaneous abortion was seen in female employees with “high potential 
26 
exposure” to ethylene glycol ethers (EGEEA and diethylene glycol dimethyl ether) 
(RR = 2.8; 95% CI:1.4 – 5.6) as well as a significantly elevated risk for subfertility 
(OR = 4.6; 95% CI: 1.6 – 13.3). Both of these effects showed a tendency to 
increase with increasing exposure. No increase in frequency of spontaneous 
abortion or significant increase in risk of subfertility was observed among the 
wives of employed men. No individual exposure measurements were made. 
Average levels < 0.2 ppm for ethylene glycol ethers were reported from a few 
measurements at places with potentially high exposure. Skin contact was 
mentioned as likely to be a more important exposure route, since ethylene glycol 
ethers can penetrate protective gloves. Simultaneous exposure to n-butyl acetate, 
N-methyl-2-pyrrolidine and xylene occurred, but it was reported that no over-
frequency of the studied effects was seen with exposure to these substances only. 
The authors report that because simultaneous exposure to hexamethyl disilazine 
also occurred, the effect of ethylene glycol ethers alone could not be assessed. A 
small prospective study at the same factories covered 148 women who planned  
to become pregnant. The women submitted morning urine samples that were 
analyzed for HCG and steroid hormones, as well as daily reports on work-related 
exposures. It was reported that four of six conceptions ended with subclinical or 
clinical miscarriages in women potentially exposed to ethylene glycol ether (26). 
In a retrospective nested case-control study by the British HSE, based on 2207 
women who worked in the semiconductor industry, 36 cases (women with 
spontaneous abortions) were matched to 80 controls. No significant elevation  
in risk for miscarriage was seen in the 1987 – 1993 period, either in general,  
for specific job groups (e.g. photolithographers), or for any specific chemical 
exposure. However, the study was made when ethylene glycol ethers were being 
phased out, and only two cases and 10 controls were judged to have been exposed 
during pregnancy. No exposure measurements are presented, but the authors 
report that company data indicated average levels of ethylene glycol ethers  
were about the same as those in the United States. They stated that existing 
epidemiologic data (in 1999) allowed no conclusions regarding a connection 
between risk of spontaneous abortion and ethylene glycol ether exposure in  
the semiconductor industry (23). 
A possible connection between congenital malformations and glycol ether 
exposure during the first trimester was reported in a West European case-control 
study. For birth defects of the harelip type, the data indicated higher risk with 
higher exposure (no air concentrations are given in the study). It was reported, 
however, that only one woman had been exposed to ethylene glycol ether or to 
acetates of the EGME/EGEE type (15, 33). A similar case-control study made 
subsequently with data from the Slovak Republic covers 15 women who had been 
potentially exposed to glycol ethers (≥ 7 with possible exposure to EGEE). Ten  
of these 15 women were in the group judged to have the highest potential for 
exposure (7 cases, 3 controls). The OR for “all congenital malformations” in  
this group was 2.7 (95% CI: 0.7 – 11) (16). Maldonado et al. (59), on the basis  
of sensitivity analyses, state that these studies are not conclusive. 
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Animal data 
EGEE and EGEEA have been studied in numerous animal experiments, with 
different methods of administration and different species, and it must be regarded 
as proven that these ethylene glycol ethers have toxic effects on reproduction in 
both sexes (46, 68). Reduced testis and epididymis weights, histological changes 
in testes, abnormal sperm, reduced sperm motility, lower sperm counts and at 
higher doses testicular atrophy and no sperm at all have been observed in male 
animals. The changes were partly or completely reversible, even after exposure  
to high doses (40, 68, 70, 74, 98). Administration of EGEE/EGEEA to female 
animals has had such results as prolonged gestation, death of embryos and fetuses, 
congenital malformations, inhibited growth and effects on CNS functions of the 
young (59, 68, 98). 
 
Effects on male animals 
In an inhalation study in which rabbits and rats were exposed to 25, 100, or 400 
ppm EGEE 6 hours/day, 5 days/week for 13 weeks, rabbits in the high-dose group 
showed effects in the form of reduced testes weights, and 3/10 animals had slight 
degenerative changes in testes. No treatment-related effects on testes were 
observed in the rats at any dose level (5). The NOAEL for rabbits (100 ppm)  
was calculated by the authors to correspond to about 50 mg/kg b.w./day (100% 
uptake was assumed).  
A study from 1971 reports testicular damage in rats after daily subcutaneous 
injections of 400 µl EGEE/kg b.w. 7 days/week for 4 weeks; no such effects were 
seen at 200 µg/kg b.w. (186 mg/kg/day) (80). In the same study, oral doses of 
EGEE were given to dogs and rats 7 days/week for 13 weeks. Histopathological 
changes in testes were observed in both species with administration of 186 mg/kg 
b.w./day, but no such changes were reported at a dose level of 93 mg/kg b.w./day 
(80). 
Oral doses of 150 or 300 mg EGEE/kg b.w. were given to rats 5 days/week for 
6 weeks. Effects noted at the higher dose level included significantly lower testes 
weights, fewer spermatids in testes, decreases in epididymal sperm count, and 
higher proportions of abnormal sperm. Significant effects were also seen at the 
lower level (the two latter effects), but only in the group with “sexually active” 
males (41). In a more recent study in which rats were given 100, 200, 400 or  
800 mg EGEE/kg b.w. 6 days/week for 4 weeks, significantly lower epididymal 
weights were observed at dose levels ≥100 mg/kg/b.w. and lower testes weights  
at ≥ 400 mg/kg/b.w. Histopathological examinations of the testes revealed dose-
dependent effects on spermatogenesis at levels ≥ 200 mg/kg b.w. Reduced weight 
gain was also observed at these levels (99). Significantly lower testes weights  
have been reported in other studies in which rats were given oral doses of EGEE 
(6 times/week, 4 weeks) at dose levels ≥150, but not ≤100, mg/kg b.w. (13, 100). 
Histopathological findings (dose level 150 mg/kg) included degenerative changes 
in testes with necrotic gametes (spermatogonia, spermatocytes) and hyperplasia  
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of Leydig cells, but no noteworthy epididymal changes other than lower weights 
(100).  
In an NTP study (reviewed briefly in References 8 and 46) EGEE was given  
to rats in drinking water for up to 13 weeks. Doses (1250 – 20,000 ppm) were 
equivalent to 100 – 2200 mg/kg b.w./day. Among reported effects were testicular 
degeneration in all animals at dose levels ≥5000 ppm. Significantly lower sperm 
concentrations were noted at levels ≥2500 ppm (not examined at 1250 ppm). In 
60-day exposure studies, moderate to pronounced testicular degeneration was seen 
at 10,000 and 20,000 ppm, but no effects were seen at 5000 ppm. The animals  
had only partially recovered 30 to 56 days after exposure was stopped. 
In studies of mice it was found that esterification of EGEE to its acetate did  
not affect the degree of testicular toxicity (63). It has been shown in rats that 
simultaneous exposure to other solvents such as toluene and xylene can affect the 
metabolism of EGEE/EGEEA, reducing the formation of the active metabolite 
EAA and accordingly reducing the toxic effect on testes (13, 100). 
 
Effects on female animals/fetuses 
Significant reduction in length of the estrous cycle was reported in rats given 
drinking water containing 10,000 ppm EGEE for up to 13 weeks. The EGEE 
concentrations (1250 – 20,000 ppm) were equivalent to 100 – 2200 mg/kg 
b.w./day (see above, NTP study cited in 8, 46). 
When pregnant rats were exposed by inhalation to 130, 390 or 600 ppm EGEEA, 
resorption at the highest dose level was 100% (Table 4). At 390 ppm there were 
increased resorptions, lower fetus weights and increases in cardiovascular defects 
and skeletal variations (possibly also skeletal malformations). A significant increase 
of skeletal variations (p<0.05) and somewhat lower fetal weights (p<0.05) were 
also observed at 130 ppm. One fetus from this group had a heart defect, and the 
authors concluded that exposure to both 130 and 390 ppm had teratogenic effects 
and caused growth retardation in rats. “No overt toxicity” was reported in the 
mothers, but no data were presented. The weight reductions observed at the higher 
exposure levels were attributed to the increase in resorptions (67). 
In a study in which rats and rabbits were exposed to 50, 100, 200 or 300 ppm 
EGEEA 6 hours/day during gestation, maternal toxicity was reported in both 
species at air levels ≥ 100 ppm (Table 4). Significantly lower fetal weights and 
increases in malformations were seen in the rats at levels ≥200 ppm. Variations 
(not described as malformations) were seen at all dose levels, though at 50 ppm 
only in the form of reduced ossification. In the rabbits, there were more absorbed 
litters, more nonviable embryos per litter, and more malformations at levels ≥ 200 
ppm. At 300 ppm malformations were noted in all living embryos (only 3 litters). 
Increases in skeletal variations were noted at dose levels ≥100 ppm. The NOEL 
for developmental toxicity given in this study was 50 ppm for both species (88). 
Both EGEEA and EGEE were used in another inhalation study with pregnant 
animals (20). Rabbits were exposed to 25, 100 or 400 ppm EGEEA 6 hours/day: 
effects on body weight and food intake of the mothers were documented at all 
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exposure levels, but were significant only at 400 ppm. Marginal effects on 
hematological parameters (mothers) are also reported at 400 ppm. Fetuses in this 
group had skeletal malformations and showed evidence of toxicity (Table 4). At 
100 ppm there were slight indications of developmental toxicity, including lower 
weight and retarded ossification, and 25 ppm was considered to be the NOEL for 
developmental toxicity. When rabbits were exposed to EGEE (10, 50 or 175 ppm, 
6 hours/day), no effects were observed in the mothers (body weight, clinical 
observations) at any dose level, but hematological examinations were not made. 
Increase of skeletal variations in young, and one with a cardiovascular defect, 
were seen at 175 ppm, and 50 ppm was given as the NOEL for developmental 
toxicity for rabbits (Table 3). 
In the same study (20), rats (24 animals/group) were exposed to 10, 50 or 250 
ppm EGEE 6 hours/day (Table 3). Minor changes in blood profile were seen in  
the mothers at 250 ppm. Increase of late intrauterine deaths, lower fetal weights 
and skeletal changes in fetuses were also reported at this level. At 50 ppm there 
was an elevated incidence of small skeletal variations of unclear significance 
(partially ossified sternum, incompletely ossified neck vertebra, extra ribs). The 
authors regarded this exposure level as slightly toxic to fetuses (LOEL), and 10 
ppm was set as the NOEL for developmental toxicity (20). The observations of 
minor skeletal variations at 50 ppm are not reported in detail and are hard to 
evaluate. These data have been reassessed in later studies by other authors, who 
set the NOEL in this study at 50 ppm for developmental toxicity to rats (73, 83). 
Exposure of pregnant rabbits to 615 ppm EGEE for 7 hours/day during gestation 
resulted in severe effects on the mothers and 100% resorbed fetuses (Table 3). 
Exposure to 160 ppm on the same schedule yielded a significant increase of 
resorbed fetuses and elevated incidences (p<0.05) of cardiovascular defects, minor 
renal anomalies and skeletal variations. No significant effect on growth (length, 
weight) of fetuses was seen, however, nor was there any effect on fertility, 
expressed as number of implantations per female. Effects on maternal body weight 
were also slight in this group (160 ppm). In the same study, 100% resorption was 
observed in pregnant rats exposed 7 hours/day to 765 ppm EGEE, either during 
gestation alone or in combination with additional exposure to 650 ppm EGEE for 
three weeks before mating. With exposure to 200 ppm EGEE during gestation, 
either alone or in combination with exposure to 150 ppm before pregnancy, there 
was significantly worse intrauterine growth and an increased incidence (p<0.05)  
of minor cardiovascular defects and skeletal variations (Table 3). There were no 
reported indications of toxicity in the mothers exposed to 200 ppm EGEE, although 
relative organ weights were sometimes affected (histological examinations were 
made). Exposure of females prior to but not during gestation (150 ppm or 650 ppm) 
had no significant effects on fetuses or on fertility. The authors concluded that 
EGEE is embryotoxic and teratogenic to both species (3, 35). 
There is a study in which female rats were exposed to 100 ppm EGEE 7 
hours/day on days 7 – 13 or 14 – 20 of gestation and behavior tests were given  
to the pups (including neuromuscular function, learning) when they were 10 to 90 
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days old (a few animals per test) and neurotransmitters were studied in newborn 
and 21-day-old pups. The only effect on the mothers that was observed in the 
study was a somewhat prolonged gestation for the group exposed on days 14 – 20. 
Effects on the behavior tests were observed with intrauterine exposure on days  
7 – 13 as well as days 14 – 20. Effects on neurochemical parameters were also 
observed. There was a reduction of noradrenaline in newborns (both exposure 
periods). Pups 21 days old with prenatal exposure on days 7 –13 had elevated 
levels of acetylcholine and/or noradrenaline in various parts of the brain and an 
increase of dopamine in the cerebrum, whereas intrauterine exposure on days  
14 – 20 resulted in elevated levels of acetylcholine, dopamine and serotonin in the 
cerebrum. With simultaneous maternal exposure to ethanol (per os) and 100 ppm 
EGEE intrauterine on days 7 – 13, the behavioral and neurochemical effects on  
the pups were less severe than with exposure to EGEE alone, but simultaneous 
exposure on days 14 – 20 seemed to have the opposite effect (64, 65, 66). 
Rats were given EGEE by gavage in doses of 12, 23, 47, 93, 186 or 372 mg/kg 
b.w./day (12.5, 25, 50, 100, 200 or 400 µl/kg/day) 7 days/week on days 1 to 21  
of gestation. At 93 mg/kg/day there were lower fetal weights and more skeletal 
variations, and this was termed an “effect level.” At 47 mg/kg/day there was a 
somewhat higher proportion of fetuses with minor deviations, and this was termed 
an incipient effect level (“beginnender effect level.”). The reported NOEL for 
effects on reproduction was 23 mg/kg/day. When the same doses of EGEE  
were given in the form of subcutaneous injections (25, 50, 100 µl/kg/day),  
93 mg/kg/day was determined to be the “effect level,” and 47 mg/kg/day the 
NOEL for rats (80). 
Effects on reproduction were also noted when undiluted EGEE and EGEEA 
were applied to the skin of rats. Indications of mild toxicity (ataxia) in the mothers 
and 100% fetal death were seen after application of 465 mg (0.5 ml) EGEE, 4 
times/day on days 7 – 16 of gestation. At a lower dose (about 230 mg; 0.25 ml)  
of EGEE there were living fetuses in 11 of 21 animals, lower numbers of living 
fetuses per litter, lower fetal weights and higher incidences of skeletal effects and 
cardiovascular malformations. There was some inhalation exposure: air levels  
of 37 – 68 ppm were reported for the high-dose group (36). Similar results were 
obtained in a study with skin application of equimolar amounts of EGEE (about 
230 mg; 0.25 ml) and EGEEA (340 mg; 0.35 ml). No clinical indications of 
toxicity were observed, but EGEEA reduced weight gain in the mothers somewhat 
more than EGEE. EGEEA was also a bit more embryotoxic and fetotoxic than 
EGEE (more totally resorbed litters, more dead embryos per litter). The spectrum 
and frequency of malformations and variations were quite similar for the two 
substances. In all, 21/34 (EGEE) and 8/10 (EGEEA) fetuses had some type of 
malformation (cardiovascular malformations in 9 and 5 fetuses respectively), 
compared with 3/87 in controls (37). 
Physiologically based pharmacokinetic (PBPK) models were used to extrapolate 
the NOEL for developmental toxicity obtained in an animal study with EGEE 
(Reference 20, see above), 50 ppm, to an exposure level for a pregnant woman. 
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Exposure to 25 ppm EGEEA 8 hours/day, 5 days/week for 38 weeks was 
calculated to give the same average concentration of EAA in blood (daily blood 
AUC: area under curve) and 40 ppm EGEEA the same maximum concentration  
of EAA in blood, as 50 ppm for the rats. The same method was used to calculate 
that the LOEL for developmental toxicity given by Tyl et al. (Reference 88, see 
above), 100 ppm (rats), should be equivalent to 55 ppm (average) and 80 ppm 
(maximum) for a pregnant woman. Skin exposure was assumed to be minimal to 
nonexistent (25). In a later work it is observed that 25 ppm could be regarded as  
a level for EGEE and EGEEA equivalent to the 50 ppm NOEL for rats (83). 
Dose-effect/dose-response relationships 
It is hard to draw any quantitative conclusions on dose-effect or dose-response 
relationships for EGEE and EGEEA from existing human studies, because 
exposures are uncertain. There may be skin uptake by direct contact with the 
liquid, as well as skin penetration by vapor, which can lead to underestimates of 
exposure when exposure levels are derived from air samples. Effects on blood 
profile and sperm have been reported in studies with average air levels of 
EGEE/EGEEA in the neighborhood of 2 to 10 ppm (estimates from Table 2),  
but with a few averages (TWA) up to 24 ppm and an unknown, but probably high, 
contribution from skin exposure (Table 2). Spontaneous abortions and reduced 
fertility have also been reported in some studies of women occupationally exposed 
to very low air concentrations of EGEE/EGEEA (and probably high skin uptake), 
but these epidemiologic data allow no conclusions on the importance of 
EGEE/EGEEA relative to that of other workplace exposures. 
Effects of inhalation exposure to EGEE and EGEEA observed in laboratory 
animals are summarized in Tables 3 and 4. Hematological effects have been 
observed in animals exposed to 100 ppm EGEEA by inhalation, but no significant 
hematological changes were seen at 50 ppm (88).This level of EGEE and EGEEA 
has also been reported to be the NOEL for developmental toxicity (20, 73, 83, 88). 
In an incompletely reported study, however, the LOEL for rats was given as 50 
ppm (20). At air levels around 100 ppm effects on young, including lower fetal 
weights, increase of skeletal variations and effects in behavior tests, have been 
reported in several studies. At higher exposure levels, increases in malformations 
have also been observed. Effects on testes have been seen in rabbits exposed by 
inhalation to 400 ppm EGEE, but not 100 ppm: 100 ppm was calculated to 
correspond to about 50 mg/kg/day, assuming 100% uptake (5). Assuming 60% 
respiratory uptake, the inhalation dose would be about 30 mg/kg b.w./day. 
Effects on reproduction have also been demonstrated in rats after skin 
application of undiluted EGEE and EGEEA. Application of 465 mg (0.5 ml) 
EGEE 4 times/day on days 7 – 16 of gestation resulted in 100% fetal death. Air 
concentrations of 37 to 68 ppm were reported. With application of about 230 mg 
(0.25 ml) EGEE, living fetuses were seen in 11/21 animals; there were reduced 
numbers of living fetuses/litter, reduced fetal weights and higher incidences of 
skeletal effects and cardiovascular malformations (36). With skin application  
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of equimolar amounts of EGEE (about 230 mg; 0.25 ml) and EGEEA (340 mg; 
0.35 ml), EGEEA was found to be a bit more embryotoxic and fetotoxic than 
EGEE, but the spectrum and frequency of malformations and variations were  
quite similar for both substances (37). 
In animal studies in which EGEE was given orally, effects on blood profile  
have been seen at dose levels around 90 – 150 mg/kg b.w./day (80, 100). In one  
of these studies a NOEL of about 50 mg/kg b.w./day was given for changes in 
blood profile (dogs) (80). In the same study, lower fetal weights and more skeletal 
variations were observed in rats at a dose level of about 90 mg/kg b.w./day, 
possibly also at about 50 mg/kg b.w./day (incipient effect level, “beginnender 
effect level.”), and the NOEL reported for reproduction effects was 23 mg/kg 
b.w./day. For subcutaneous injections of EGEE (rats) the reported level for effects 
on reproduction was about 90 mg/kg b.w./day, and the NOEL about 50 mg/kg 
b.w./day (80). Effects on testes and sperm have been reported with repeated oral 
administration of EGEE at dose levels around 150 – 200 mg/kg b.w. (13, 41, 80, 
99, 100). 
On the basis of PBPK models and EAA concentrations in blood, it has been 
calculated that an exposure level (8 hours/day, 5 days/week, 38 weeks) of 25 ppm 
EGEE or EGEEA for a pregnant woman corresponds to the NOEL for develop-
mental toxicity, 50 ppm, for rats (25, 83). 
Conclusions 
Both animal data and data from occupational exposures to EGEE and EGEEA 
indicate that the critical effects are those on blood profile and reproduction. The 
two substances can be regarded as toxicologically similar. EGEE/EGEEA are 
absorbed effectively via both respiratory tract and skin (also in vapor form) and 
skin uptake can be considerable. 
Effects on blood profile and reproduction have been reported in workers with 
occupational exposures of 2 – 10 ppm. Air levels are an unreliable way to assess 
exposure risk, since skin uptake frequently occurs. Similar effects are observed  
in animals, but at higher exposure levels. 
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Table 2. Reports of occupational exposure to EGEE/EGEEA associated with effects on health (or their 
absence). 
 
Air levela, 
ppm; average 
(range) 
EAA in urine, 
mg/g creatinine; 
average (range) 
Exposure situation/ 
occupation 
Number of 
subjects 
Observed effects Ref. 
 
EGEE 
     
2.6 
(nd-21.5) b 
 Ship painters, 
probable high skin 
exposure, also EGME 
(TWA 0.8 ppm, 
range 0-5.6 ppm) 
94 painters 
55 controls 
Hb <140 g/l: 9 painters,  
0 controls, 
granulocytopenia:  
5 painters (not the same),  
0 controls 
79, 
93 
2.6 
(nd-21.5) b 
 Same as above 73 painters 
40 controls 
Fewer sperm per ejaculate 
(nonsmokers), p=0.05; ≤20 
million sperm/ml: 10/73 vs 
2/40, p=0.12 (4 painters,  
0 controls virtually lacking  
in sperm) 
79, 
94 
6.6 
(nd-23.8) c 
- 
(nd-163) 
Metal casting, 
probable skin 
exposure 
37 exposed 
38 controls 
Fewer sperm per ejaculate; 
p=0.05; ≤20 million 
sperm/ml: 6/37 vs 4/38; 
not significant 
14, 
74 
EGEEA 
     
0.51 
(0.15-3.03) 
pre-shift e 0.12  
(0.02-0.88) 
post-shift e 0.16 
(0.02-1.24) 
Production of LCD 
screens, no direct 
skin contact 
52 exposed 
55 controls 
No effect on studied 
menstruation parameters 
12 
1.8 
(nd-8.1) 
0.6 
(nd-15.1) 
Ship painters, 
probable high skin 
exposure; also 
toluene, xylene, 
MIBK 
27 painters 
41 controls 
Leukopenia: 1 painter  
(4200 cells/µl),  
0 controls 
52 
3.0 
(nd-18.3) d 
9.2 
(nd-227.3) 
Same as above 30 painters 
41 controls 
Lower numbers of white 
blood cells, larger red 
blood cells; leukopenia 
(<4500 cells/µl):  
5 painters, 0 controls 
52 
4.9 
(1.4-8.7) 
- Silk screening 
factory, possible skin 
exposure; also some 
toluene and MIBK 
17 exposed 
(men) 
29 controls 
(men) 
No significant exposure-
related effects on blood 
profile  
11, 
58 
9.3  
(4.1-16.5) 
. Silk screening 
factory, probable skin 
exposure; also some 
toluene and MIBK 
12 exposed 
(women) 
27 controls 
(women) 
1998; lower Hb (131 vs  
138 g/l), lower hematocrit  
(40 vs 42%) 
11, 
58 
 
nd = not detectable. 
a
 personal monitors, 8-hour time-weighted averages. 
b
 the authors warn that the measurements may not be representative and that higher exposures may have occurred. 
c
 the authors report analysis problems and warn that actual air levels may have been higher. 
d
 personal monitors, at least 6 hours. 
e
 reported as EGEEA in urine. 
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Table 3. Some animal experiments with inhalation a of EGEE. 
 
Air level b 
ppm 
(mg/m3) 
Exposure Species Effects Ref. 
 
10 (37) During 
gestation, 
6 hrs/day, 
days 6-18 
(rabbit) 
days 6-15 (rat) 
Rabbit 
Rat 
Rabbits: no effects. 
Rats: NOELc in this study for 
developmental toxicity. 
20 
25 (93) 6 hrs/day,  
5 days/week,  
13 weeks 
Rabbit 
Rat 
Both species: increased tear flow and nasal 
secretion (not dose-related). 
5 
50 (187) During 
gestation, 
6 hrs/day, 
days 6-18 
(rabbit) 
days 6-15 (rat) 
Rabbit 
Rat 
Rabbits: NOEL in this study for 
developmental toxicity. 
Rats: NOEL in this study for maternal 
toxicity. NOELc in this study for 
developmental toxicity. LOELc in this 
study for developmental toxicity (increase 
of minor skeletal variations). 
20, 
73, 
83 
100 (390) 6 hrs/day, 
5 days/week, 
13 weeks 
Rabbit 
Rat 
Rabbits: NOAEL in this study. 
Both species: increased tear flow and nasal 
secretion (not dose-related). 
5 
100 (374) During 
gestation, 
7 hrs/day,  
days 7-13  
or 14-20 
Rat Somewhat longer gestation with exposure 
on days 14-20.  
Developmental toxicity: effects on 
behavior tests and neurochemical 
parameters (both exposure periods). 
64, 
65, 
66 
150 (561) Before mating, 
7 hrs/day,  
3 weeks 
Rat No significant effects on fetuses/embryos 
or on fertility. 
3, 
35 
160 (598) During 
gestation, 
7 hrs/day,  
days 1-18  
Rabbit Maternal effects: higher relative liver 
weight, lower food intake (little effect on 
weight gain). 
Developmental toxicity: higher incidence 
of resorbed fetuses, malformations 
(including heart), minor renal anomalies 
and skeletal variations. 
3, 
35 
175 (655) During 
gestation, 
6 hrs/day,  
days 6-18  
Rabbit NOEL in this study for maternal toxicity. 
LOEL in this study for developmental 
toxicity: higher incidence of skeletal 
variations (retarded ossification, extra 
ribs), one fetus with cardiovascular defect. 
20 
200 (748) During 
gestation, 
7 hrs/day, 
days 1-19 
Rat Maternal effects: higher relative liver, 
kidney and spleen weights. 
Developmental toxicity: poorer intrauterine 
growth, higher incidence (p<0.05) of 
minor cardiovascular defects and skeletal 
variations (including retarded ossification, 
extra ribs). 
3,  
35 
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Table 3. Cont. 
 
Air level b 
ppm 
(mg/m3) 
Exposure Species Effects Ref. 
 
150 (561) 
+ 200 (748) 
Before mating, 
7 hrs/day,  
5 days/week,  
3 weeks  
+ days 1-19  
of gestation 
Rat Developmental toxicity: poorer intrauterine 
growth, higher incidence of skeletal 
variations (including retarded ossification, 
extra ribs). 
3, 
35 
250 (935) During 
gestation, 
6 hrs/day, 
days 6-15 
Rat LOEL in this study for maternal toxicity; 
minor changes in blood profile (lower Hb, 
hematocrit; smaller red blood cells). 
Developmental toxicity: more late 
intrauterine deaths, skeletal changes (e.g. 
retarded ossification, variations), lower 
fetal weights. 
20 
370 (1370) 7 hrs/day,  
5 days/week, 
5 weeks 
Rat Higher iron accumulation and reduction of 
myeloid cells in spleen, higher numbers of 
immature granulocytes. 
96 
400 (1480) 6 hrs/day, 
5 days/week, 
13 weeks 
Rabbit 
Rat 
Rabbit: LOAEL in this study: blood profile 
changes, poorer weight gain, lower testis 
weights, in 3/10 animals slight 
degenerative changes in testes. 
Rat: NOAEL in this study. 
Both species: increased tear flow and nasal 
secretion (not dose-related). 
5 
615 (2300) During 
gestation, 
7 hrs/day,  
days 1-18 
Rabbit Severe maternal toxicity: higher mortality, 
lower body weight, higher relative liver 
and kidney weights.  
100% resorbed fetuses. 
3, 
35 
about 800 
(about 
3000) 
7 hrs/day, 
5 days/week, 
12 weeks 
Dog Smaller red blood cells with changes 
(hypochromia, polychromatophilia); slight 
reductions in number of red blood cells, 
hematocrit and Hb; large increase in 
proportion of immature granulocytes. No 
noteworthy changes seen in histological 
examinations (including liver, kidneys, 
lungs, spleen, heart). 
97 
 
a
 whole-body exposure. 
b
 conversion factors: 1 ppm = 3.74 mg/m3; 1 mg/m3 = 0.27 ppm (unless others are given in the 
study). 
c
 10 ppm reported by the authors to be the NOEL, and 50 ppm the LOEL, for developmental 
toxicity (rats) (20). On the basis of the same data, 50 ppm was judged by other authors to be the 
NOEL in this study (73, 83). 
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Table 4. Some inhalation studies a in which laboratory animals were exposed to EGEEA 
during gestation. 
 
Air level b 
ppm 
(mg/m3) 
Exposure Species Effects Ref. 
 
25 (137) 6 hours/day 
days 6-18 
Rabbit NOEL in this study for developmental toxicity. 20 
50 (274) 6 hours/day 
days 6-18 (rabbit) 
days 6-15 (rat) 
Rabbit 
Rat 
NOEL in this study for maternal toxicity (both 
species).  
NOEL in this study for developmental toxicity 
(both species). 
88 
100 (548) 6 hours/day 
days 6-18 (rabbit) 
days 6-15 (rat) 
Rabbit 
Rat 
LOEL in this study for maternal toxicity (both 
species). Rabbit: reduced thrombocyte counts, 
poorer initial weight gain. Rat: reduced Hb, 
hematocrit, number and size of red blood cells; 
higher absolute and relative liver weights. 
LOEL in this study for developmental toxicity 
(both species). Rabbit: increase of skeletal 
variations. Rat: increase of variations. 
88 
100 (548) 6 hours/day 
days 6-18 
Rabbit NOEL in this study for maternal toxicity. 
LOEL in this study for developmental toxicity: 
lower fetal weights, higher incidence of skeletal 
variations (retarded ossification). 
20 
130 (712) 7 hours/day 
days 7-15 
Rat LOEL in this study for developmental toxicity: 
somewhat lower fetal weights, increase of 
skeletal variations; one fetus with a heart defect. 
67 
200 
(1096) 
6 hours day, 
days 6-18 (rabbit) 
days 6-15 (rat) 
Rabbit 
Rat 
Maternal toxicity: Rabbit: lower thrombocyte 
counts, blood in urine, poorer initial weight 
gain. Rat: changes in blood profile (reduced 
number and size of red blood cells, fewer 
thrombocytes, lower Hb and hematocrit, more 
white blood cells); poorer weight gain, higher 
relative and absolute liver weights. 
Developmental toxicity: Rabbit: more resorbed 
litters and nonviable fetuses; more 
malformations (including heart) and variations. 
Rat: lower fetal weights, increases of skeletal 
defects and variations. 
88 
300 
(1644) 
6 hours/day 
days 6-18 (rabbit) 
days 6-15 (rat) 
Rabbit 
Rat 
Maternal toxicity: Rabbit: lower thrombocyte 
counts, increased size of red blood cells, blood 
in urine, poorer weight gain, higher absolute 
liver weights. Rat: changes in blood profile, 
poorer weight gain, higher absolute and relative 
liver weights. 
Developmental toxicity: Rabbit: resorption of 
16/19 litters, malformations in all living fetuses 
(including heart). Rat: increases in variations 
and malformations (including heart), lower fetal 
weights. 
88 
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Table 4. Cont. 
 
Air level b 
ppm 
(mg/m3) 
Exposure Species Effects Ref. 
 
390 
(2137) 
7 hours/day 
days 7-15 
Rat Developmental toxicity: increases of 
resorptions, malformations and skeletal 
variations; lower fetal weights. 
67 
400 
(2192) 
6 hours/day 
days 6-18 
Rabbit LOEL in this study for maternal toxicity: 
marginally lower Hb, lower body weights and 
food intake. 
Developmental toxicity: increases in intrauterine 
deaths, skeletal malformations, variations and 
slight defects, lower fetal weights. 
20 
600 
(3288) 
7 hours/day 
days 7-15 
Rat 100% resorptions. 67 
 
aWhole-body exposure. 
bConversion factors: 1 ppm = 5.48 mg/m3; 1 mg/m3 = 0.18 ppm (unless others are given in the  
  study). 
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Appendix 1. 
Toxicokinetic calculation of EAA in urine after exposure to EGEE 
Assumptions: 
•  Linear and time-independent kinetics, i.e. no induction, enzyme saturation etc.; 
•  One-compartment model; 
•  Exposure to 5 ppm, 8 hours/day, 5 days/week, 4 weeks; 
•  Uptake in respiratory passages is 64% (27); 
•  Volume of air inhaled in an 8-hour workday is 10 m3; 
•  The half time for excretion of EAA in urine is 21 hours (28), 42 hours (31),  
 or 60 hours (84*); 
•  42-hour recovery of EAA in urine after about 4 hours of exposure is  
 23.1% (molar basis) of the inhaled amount of EGEE (27, 28). This yields  
 a total recovery of 30.8% (molar basis) with a half time of 21 hours  
 (0.231/(1-e -In2/21-42) = 0.308); 
•  mg EAA/g creatinine is equivalent to µg EAA/minute, i.e. creatinine excretion 
 is 1 mg/minute. 
 
Table 1. Calculations made with the Berkeley Madonna program. 
 
EAA in urine 
(mg/g creatinine) 
Half time 
21 hours 
Half time 
42 hours 
Half time 
60 hours* 
 
Post-shift on Friday after 1 week   60.8   47.5   40.1 
Post-shift on Friday after 4 weeks   60.8   50.7   46.8 
 
* field study, probable skin uptake. 
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Consensus Report for Organic Acid 
Anhydrides 
June 4, 2008 
This Consensus Report constitutes a basis for assessing the risks of  
occupational exposure to the organic acid anhydrides phthalic anhydride (PA), 
trimellitic anhydride (TMA), maleic anhydride (MA), hexahydrophthalic 
anhydride (HHPA), methylhexahydrophthalic anhydride (MHHPA), 
methyltetrahydrophthalic anhydride (MTHPA), tetrahydrophthalic anhydride 
(THPA) and tetrachlorophthalic anhydride (TCPA). The present document is 
based on a criteria document produced jointly by the Nordic Expert Group and  
the Dutch Expert Committee (19), and contains additional information from 
literature searches made through September of 2007. It updates the Consensus 
Report published in 1991 (28). 
Chemical and physical data. Occurrence 
Anhydride CAS No. Abbreviation Formula Mol weight 
Phthalic anhydride 85-44-9 PA C8H4O3 148.12 
Trimellitic anhydride 552-30-7 TMA C9H4O5 192.13 
Maleic anhydride 108-31-6 MA C4H2O3 98.06 
Hexahydrophthalic  
anhydride 
85-42-7 HHPA C8H10O3 154.17 
Methylhexahydrophthalic 
anhydride 
25550-51-0 MHHPA C9H12O3 168.19 
Methyltetrahydrophthalic 
anhydride 
26590-20-5 MTHPA C9H3O3 166.19 
Tetrahydrophthalic  
anhydride 
85-43-8 THPA C8H8O3 152.16 
Tetrachlorophthalic  
anhydride 
117-08-8 TCPA C8Cl4O3 285.88 
 
 
Some physical and chemical data are presented in Table 1, and structures are 
shown in Figure 1. For PA there is a reported octanol/water distribution 
coefficient, log Pow = - 0.62 (i.e. more soluble in water than in octanol), and a 
reported odor threshold of 320 µg/m3. For MA the reported odor threshold is  
1230 µg/m3. Further data and synonyms are presented in the Criteria Document 
(19). 
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Table 1. Some chemical and physical data on organic acid anhydrides. Further data are 
presented in the Criteria Document (19). 
 
Anhydride State at room 
temperature 
Melting 
point (°C) 
Boiling point 
(°C) 
Vapor pressure 
(Pa) 
Saturation 
concentration 
(ppm) 
 
PA Crystalline 130.8 284 (subl.) <6.6 at 20°C <65 
TMA Crystalline 161 – 163.5 240 – 245 <10 at 25°C <99 
MA Crystalline 53 202 (subl.) 25 at 20°C 250 
HHPA Crystalline 35 – 36 158 (2.3 kPa)   
MHHPA Liquid - 29 120 (130 Pa)   
MTHPA Liquid  >200 0.1 at 20°C 1 
THPA Crystalline 101.9 195 (6.7 kPa) 1.3 at 20°C 13 
TCPA Crystalline 254 – 255 371 (subl.)   
 
(subl.) = sublimates 
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Figure 1. Structural formulas for the above organic acid anhydrides. 
 
Organic acid anhydrides are used primarily in the production of polyester and 
alkyd plastics (PA, TMA, MA, THPA, TCPA) and as hardeners in production of 
epoxy plastics (PA, HHPA, MHHPA, MTHPA). Organic acid anhydrides do not 
occur naturally. Occupational exposure occurs around production and handling  
of the compounds. In Sweden, the highest levels in workplace air have been 
measured around reactors being charged with the substances (PA, MA) in powder 
form, and around operations that involve heating of free organic acid anhydrides 
(HHPA, MHHPA, MTHPA). The organic acid anhydrides have low vapor 
pressures (Table 1), and exposure is therefore primarily to airborne particles. 
Particles are formed by condensation/sublimation at room temperature after  
the substances have been heated. 
A representative selection of air levels recorded with personal monitors in 
Swedish companies (unless otherwise stated) is presented below. 
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PA. Levels up to 17,000 µg/m3 have been measured around reactors being charged 
with PA powder for production of alkyd and/or unsaturated polyester resins.  
The time-weighted average (TWA) for a workshift was estimated to be about  
400 µg/m3 (31). Considerably lower averages (38 µg/m3) were measured in a later 
English study (45). Low levels of PA are also released during processing of PVC 
plastics that contain phthalates as softeners (44). 
TMA. In Sweden, levels in the range 6 – 180 µg/m3 have been measured around 
powder painting (7). In the English study mentioned above, levels up to 20,000 
µg/m3 were measured during charging of reactors; levels around other operations 
were usually below 40 µg/m3 (45). 
MA. 600 µg/m3 has been recorded around reactors being charged with MA (32). 
THPA. No exposure data for this compound were found in the literature. 
HHPA and MHHPA. These compounds are usually handled simultaneously in 
mixing. In two companies that insulate electronic components, HHPA levels up  
to 470 µg/m3 were measured around casting. Daily averages recorded by personal 
monitors were 23 – 140 µg/m3 for HHPA and 9 – 48 (with a peak value of 403) 
µg/m3 for MHHPA (47). In a Japanese company using mostly HHPA, but also 
some MHHPA, average levels of HHPA were below 40 µg/m3 (55). 
MHHPA was monitored in two electronics companies in Finland (37). Average 
exposures ranged from 68 to 118 µg/m3 for workers in condenser production, and 
levels up to 1900 µg/m3 were recorded around work at the ovens. The highest 
exposure measured at the company was 2200 µg/m3 (8-hour average). Levels  
were also quite high in adjacent offices (17 – 43 µg/m3). 
MTHPA. In a company producing barrels for grenade rifles, MTHPA levels were 
up to 380 µg/m3 with an average value of 100 µg/m3 for the most highly exposed 
group (46). Levels recorded in two Japanese companies were 5 and 26 – 64 µg/m3 
(53). 
Exposures to MTHPA and exposures to HHPA and MHHPA combined were 
monitored in a prospective study with 163 participants, made during 1988 – 1997. 
Exposure levels were derived from monitoring data and job descriptions. Average 
exposure was calculated to be 15.4 µg/m3 (TWA), with a range from below the 
detection limit (1 µg/m3) to 189 µg/m3 (49). 
TCPA: Exposure levels of 140 – 590 µg/m3 are reported in a study made at  
a Canadian company. Levels dropped to below 110 µg/m3 after intervention 
measures were taken (27). 
Uptake, biotransformation, excretion 
When volunteers were exposed to HHPA in gas form (80 µg/m3) for 8 hours,  
1 – 4% was recovered in exhaled air (17). In another study, more than 85% of 
absorbed HHPA was recovered as hexahydrophthalic acid (HHP acid) in urine 
(15). In a study with 3 volunteers, 1400 µg HHPA dissolved in vaseline (2% 
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HHPA) was placed on a total area of 2 cm2 skin under occlusion for 48 hours: 
estimated uptakes were 1.4 – 4.5%, 0.2 – 1.3%, and 0 – 0.4% (16). Uptakes  
were determined by collecting urine at 4-hour intervals for a total of 72 hours  
and analysis for HHP acid. The authors concluded that uptake of organic acid 
anhydrides by healthy skin is low. 
Lindh et al. (26) used autoradiography to map the distribution of radioactively 
labeled HHPA in guinea pigs and rats after 3 to 8 hours of inhalation exposure. 
Medium-high to high levels of radioactivity were seen in nasal and tracheal 
mucosa, whereas levels in lung tissue were minimal. Tissue-bound radioactivity 
was also seen in the digestive tract and conjunctiva, and low levels in the renal 
cortex (rats only). The animals still contained some radioactivity at least 7 days 
after the exposure. With the exception of the lungs, the radioactivity was only 
partially extractable with organic solvents and water, which indicates that it was 
covalently bound. The radioactivity in dialyzed plasma was found mostly in the 
albumin fraction (gel filtration). 
The anhydride group reacts rather quickly with amino acids and is conjugated 
with plasma proteins (19). Adducts in plasma proteins, including human serum 
albumin (HSA), have been measured in serum from workers exposed to HHPA 
and MHHPA. The half time for the adducts was about 20 days (38). Conjugation 
with hemoglobin was observed when human erythrocytes were exposed to  
HHPA and MHHPA (25). Organic acid anhydrides react with water to form the 
corresponding carboxylic acids, and are excreted in this form in urine. In persons 
occupationally exposed to 1630 µg/m3 PA there was a rise in pre-shift urine 
concentration of phthalic acid during the workweek. The half time for PA in urine 
is 14 hours. The half time for HHPA is 2 – 3 hours in urine and 1.7 – 1.8 hours in 
plasma. For workers exposed to industrial MTHPA, excretion time in urine ranges 
from 3.3 to 6 hours for the four isomers (19). 
Biological exposure monitoring 
Levels of HHP acid in plasma and urine of exposed volunteers have shown  
good correlations with air concentrations. The half time for MHHPA in urine  
of exposed workers ranged from 4 to 10 hours. There was a strong linear and 
proportional correlation between air levels and the corresponding concentrations 
in urine. Exposure to 20 µg/m3 (8-hour average) corresponds to a level of 140 
nmol MHHP acid/mmol creatinine in urine, and to about 40 nmol/l in hydrolyzed 
plasma (24). Similar studies of MTHPA-exposed persons in Japan showed that 
excretion of MTHP acid in urine increased during exposure and then declined, 
with a half time of about 3 hours. An exposure of 50 µg/m3 (8-hour average) 
corresponded to an excretion of about 900 nmol/mmol creatinine in urine (56). 
Total plasma protein adducts of HHPA and MHHPA showed a strong correlation 
to exposure as measured in the form of urine levels of HHP acid and MHHP acid 
(39). Exposure to HHPA measured as HHP acid in urine correlated well with 
HHPA-hemoglobin adducts in blood (19). 
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Available data indicate that it should be possible, for some of these substances 
(especially MHHPA and HHPA), to express a correlation between exposure and 
effect in the form of acid levels in urine or protein adducts in plasma. Such a 
procedure would be attractive since it provides an integrated measure of dose  
over a longer time and includes exposure via inhalation as well as skin uptake,  
and would thus show the effects of protective equipment. 
Toxic effects 
Human data 
Organic acid anhydrides are irritating to skin and to mucous membranes of  
eyes and respiratory organs, and cause symptoms such as itching, watery eyes, 
sneezing, runny noses, coughing and breathlessness (19). 
Rhinoconjunctivitis and/or asthma have been observed in workers exposed  
to every one of the organic acid anhydrides reviewed here except THPA. Both 
immediate and late reactions, as well as a combination of the two, have been 
demonstrated in provocation tests with PA, MA, HHPA, MTHPA and TCPA.  
The Criteria Document contains reviews of several cross-sectional studies 
presenting correlations between asthma and industrial use of organic acid 
anhydrides (19). 
Work-related respiratory problems, including asthma, may occur in exposed 
workers with IgE antibodies specific for organic acid anhydrides (sensitized) as 
well as in workers without such antibodies. It has therefore been assumed that 
there are different mechanisms behind the respiratory symptoms induced by 
organic acid anhydrides: one mechanism with an IgE-mediated allergic reaction 
(3, 18, 19) and another IgE-independent specific hypersensitivity reaction of 
unclear nature. The latter may be due to a cell-mediated allergy (13, 14). Non-
immunological mechanisms resulting from irritative/toxic effects can also result in 
respiratory symptoms (1, 29, 33). Since correlations between IgE and respiratory 
symptoms have been examined almost exclusively in cross-sectional studies, 
however, any such correlations may have been masked or underestimated. 
There are considerable data associating asthma or rhinitis with the presence of 
IgE antibodies specific for all of the organic acid anhydrides discussed here except 
THPA. Sensitization has been identified by skin prick test and by IgE antibodies 
in serum against HSA conjugates of organic acid anhydrides. The biological  
half time for the IgE antibodies after exposure is stopped is about 1 year (19). In  
a prospective study, Nielsen et al. (36) found a significant correlation between 
symptoms and specific IgE antibodies, although not all the subjects with the  
IgE antibodies had symptoms. Since the study was halted by positive tests for 
antibodies specific for organic acid anhydrides, there is no way of knowing how 
many would have developed symptoms with continued exposure. 
The question of a relationship between atopy or smoking and sensitization  
and symptom development with exposure to organic acid anhydrides has been 
addressed in numerous studies (3, 5, 6, 11, 27, 33, 35, 36, 43, 46, 47, 49, 50, 52). 
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Some studies show that smoking, and especially atopy, increase the risk of 
sensitization and symptom development, but the results are not consistent. 
Although allergic contact eczema (Type IV allergy) has seldom been described, 
IgE-mediated contact urticaria is not uncommon. PA, MA, MHHPA, MTHPA  
and HHPA have been reported to cause contact urticaria in exposed workers with 
specific IgE antibodies and positive prick tests (19). Yokota et al. (54) report a 
case of urticaria caused by MHHPA, but not HHPA, after only airborne exposure 
to both anhydrides. 
PA and MA. Workers are often exposed to these two compounds simultaneously. 
In a study of 60 workers with top exposures up to 17,400 µg/m3, Nielsen et al. 
(31) found that, of the 35 who had highest exposures (average about 400 µg/m3),  
5 had occupational asthma and 24 had occupational rhinitis (40%) and/or 
conjunctivitis (46%). Exposure time was on average 13 years. Of the 25 with 
lower exposures (below 100 µg/m3), 5 had occupational rhinitis or conjunctivitis 
and none had asthma. Average exposure time for this group was 12 years. Air 
concentrations of PA were measured with personal monitors: a total of 29 samples 
with a total sampling time of 20 hours. One subject in the high-exposure group 
and three in the low-exposure group had PA-specific IgE antibodies. The results 
indicate a primarily non-IgE-mediated effect of PA. These persons were also 
exposed to other anhydrides, including MA, but to a much lesser extent. 
In an English retrospective study of workers in three factories, who handled PA 
and MA and to some extent also TMA, there were 4 cases of sensitization among 
a total of 285 current and former employees (3). Exposures were measured with 
personal monitors, for entire shifts and also during some operations where high 
levels might be expected. The measurements were made over a period of 2 to 4 
weeks. There were 84 samples for PA, 39 for MA and 84 for TMA. Average 
exposures to PA in the three factories were 8.9, 61.9 and 11.9 µg/m3. Levels  
of MA in 2 of the factories were 2.8 and 1.8 µg/m3. TMA levels were 0.9, 0.7,  
and 0.5 µg/m3. 
There are only a few reported cases of MA-mediated asthma without simultane-
ous exposure to PA. In a study in which a provocation test was given to two MA-
exposed workers, both early and late reactions to MA were obtained (10). In 
another study a worker who had developed asthma after one month of exposure  
to MA and PA had a positive reaction to provocation with MA but no reaction  
to provocation with PA (22). 
TMA. Both immediate and late airway reactions have been reported. Symptoms  
of the late asthmatic reaction were coughing, wheezing and breathlessness 4 – 8 
hours after the exposure. “Pulmonary disease-anemia syndrome,” a specific lung 
disease which can develop into severe illness with hemorrhage, has also been 
described. Of 9 workers exposed to high levels of TMA (1700 – 3600 µg/m3) 
from powder paint, four had irritation-mediated effects and three had symptoms 
indicating an asthmatic reaction (23). During 1976 – 1987, examinations were 
given to 196 workers in a company that made TMA. IgE-mediated asthma or 
rhinitis was identified in 21 of them and late asthmatic reactions in 10. One had 
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the pulmonary disease-anemia syndrome. Only 46 persons were entirely without 
symptoms (58). In a cross-sectional study made in the same factory in 1988 – 
1989 a further 310 workers were examined, and 2 of 8 in the group with highest 
exposure to TMA (0.54 – 6500 µg/m3; geometric mean 170 µg/m3; based on 
records from 29 personal monitors) had TMA-specific IgE antibodies (59). In an 
examination of 25 workers with TMA-induced asthma, Grammer et al. (12) found 
that 88% had rhinitis, and 68% reported symptoms of conjunctivitis. The rhinitis 
had preceded the asthma in 77% of patients who had both rhinitis and asthma, and 
of those with both conjunctivitis and asthma 82% had developed the conjunctivitis 
first. Symptoms of rhinitis and conjunctivitis thus often precede the development 
of asthma. 
In a factory where TMA was the only organic acid anhydride used, 107 workers 
were given prick tests to determine the presence of TMA-specific IgE antibodies. 
Personal monitors were used to measure whole-shift exposures, and additional 
readings were taken around operations where high exposures could be expected. 
The measurements were made over a period of 2 to 4 weeks, and 49 air samples 
were analyzed. The subjects were divided into three exposure groups: <10, 10 – 
40, and >40 µg/m3. Positive responses to the prick test were obtained in 1/63,  
5/36 and 2/8 respectively. In addition, 12 subjects with work-related respiratory 
symptoms were each matched to 4 controls in a case-control study. Positive  
skin prick tests and work-related respiratory symptoms were significantly more 
common among the workers exposed to more than 10 µg/m3 TMA than among 
those with lower exposures (3). 
HHPA and MHHPA. In two Swedish companies where epoxy plastics containing 
HHPA and MHHPA were used to insulate electronic components, the highest 
levels of HHPA (130 and 470 µg/m3) were measured around casting. MHHPA 
levels did not exceed 400 µg/m3. The highest exposure average was140 µg/m3. 
Over a period of 2 years a total of 167 air samples were taken in the casting 
department, using both personal and stationary monitors. HHPA-specific 
antibodies were identified in 23 (24%) of the exposed workers (47). 
In a factory that manufactured condensers, air levels of HHPA and MHHPA 
were measured with personal (122 samples, total sampling time 427 hours) and 
stationary (97 samples) monitors on 10 occasions during a one-year period. Work-
related symptoms were significantly more frequent in exposed workers (n = 154) 
than in a reference group from a mechanical industry: eye symptoms 23% vs. 
14%, nasal symptoms 28% vs. 16%, nosebleeds 8% vs. 0%, and symptoms 
involving the lower respiratory tract 10% vs. 4%. IgE antibodies specific for one 
or both anhydrides were identified in 34 (22%) of the subjects. The symptoms 
were correlated to exposure and to the antibodies. The workers were divided into 
three exposure categories based on current exposure (HHPA + MHHPA): <10, 10 
– 50, and >50 µg/m3. There were significant correlations between exposure and 
symptoms involving eyes, nose and lower respiratory tract. The proportion of 
workers with specific IgE antibodies was fairly high even in the low-exposure 
group (13% HHPA, 15% MHHPA), although the prevalence of symptoms was  
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not significantly elevated (35). Asthma and rhinitis/conjunctivitis in workers 
exposed to HHPA had been reported in an earlier American study (30).  
In a Japanese company that used HHPA and MHHPA as epoxy hardeners,  
a cross-sectional study was made several years after levels of organic acid 
anhydrides had been reduced to below 40 µg/m3. Elevated levels of specific IgE 
were seen in 8 (25%) of 32 workers, and 5 of the 8 had work-related symptoms 
involving the eyes and nose. The symptoms usually appeared during operations 
when brief exposure peaks might be expected. The other 24 persons reported no 
work-related health concerns. Four of the 8 IgE-positive subjects were believed  
to have been sensitized by previous high exposures (55). 
MTHPA. In a Swedish study of a group of 144 workers with current exposure  
and 26 workers with previous exposure to MTHPA, 31% had work-related eye 
symptoms, 53% had nasal symptoms, 26% had throat symptoms, and 11% 
suffered from asthma. Corresponding figures for a control group of 33 persons 
from a nearby machine shop where exposure to irritating substances was low were 
0, 9, 6 and 0% respectively. There were statistically proven correlations between 
exposure and symptoms involving eyes and upper respiratory tract, as well as dry 
cough. Skin prick tests with a conjugate of MTHPA and HSA were positive for 25 
persons, and 28 had MTHPA-specific IgE antibodies. None of the controls had a 
positive prick test or specific antibodies. A total of 56 air samples were taken (50 
– 300 minutes per sample), mostly with personal monitors, but stationary monitors 
were also used. The total sampling time was 222 hours. The concentration of 
MTHPA was below 150 µg/m3. Among workers exposed to 5 – 20 µg/m3 (n = 
70), 56% had symptoms involving eyes and upper respiratory tract, 9% had 
asthma, and 16% had the specific antibodies. In the group (n = 55) with exposure 
to 20 – 150 µg/m3, 65% had eyes and upper respiratory symptoms, 11% had 
asthma and 22% had the specific antibodies. Five sensitized workers who had left 
the company no longer had symptoms and were less reactive to methacholine,  
but 41 workers who had remained at the company reported no improvement  
in symptoms despite a tenfold reduction in exposure (33, 46). 
Examinations were given to 28 workers exposed to MTHPA levels in the  
range 1.09 – 22.4 µg/m3 at two Japanese companies. The air level of MTHPA  
was measured twice a year with stationary monitors. Specific IgE antibodies  
were identified in 9 (32%) of the workers, and 8 of them had upper respiratory 
symptoms (51). In a subsequent study of 148 workers from the same two 
companies, 66% were found to have specific IgE antibodies (52). In a study 
(probably with the same study base used in Yokota et al. 1997 (52) but with a 
different selection) of two Japanese factories (A and B) producing condensers, 
MTHPA levels in the assembly and inspection areas were 26 to 64 µg/m3 
(geometric means) with a range of 7.5 – 421 µg/m3 in factory A and 4.9 – 5.5 
µg/m3 (range 0.7 – 22.4 µg/m3) in factory B. MTHPA levels in air were measured 
with stationary monitors for 60 to 120 minutes during the afternoons, when they 
had reached a plateau phase. The measurements were made twice a year for two 
years. In factory A, 24 of 37 workers (65%) had MTHPA-specific IgE antibodies, 
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and in factory B 38 of 58 (66%), but the sensitization might have been a 
consequence of previous high exposures. At both factories, work-related 
symptoms involving eyes and nose were significantly more common among  
the sensitized workers than among those not sensitized. Symptoms among 
sensitized persons were more common in factory A than in factory B. No cases  
of asthma were reported. The authors report that “…the minimal level of MTHPA 
that was associated with work-related symptoms was 15 – 22 µg/m3” (53), but it  
is not clear how they arrived at this figure. 
In a German study made in 1991, examinations were given to 110 workers 
exposed to HHPA and MTHPA. Twenty were found to be sensitized (presence  
of specific IgE antibodies and/or positive prick test with organic acid anhydride), 
and those who had work-related symptoms were further tested with inhalation 
provocation. The authors report that the clinical relevance of sensitization was 
confirmed in six of them. Air quality at the workplace was improved after the 
study, and the production process was modified to use only MTHPA. When the 
workers were again examined in 1995, air levels of MTHPA were <0.5 – 36 
µg/m3 (3 readings from personal and 5 from stationary monitors). At that time  
27 of the workers examined in 1991 had left the company. The relative risk for 
leaving the company was 2.6 (95% CI: 1.4. – 4.9) for sensitized compared to non-
sensitized workers. Ten of the 20 sensitized workers identified in the 1991 study 
were still at the company in 1995, including 5 of the 6 judged in 1991 to have 
clinically relevant sensitization. All 5 of them reported fewer symptoms, and 4 of 
5 reported less severe symptoms than in 1991 (8, 9). Unfortunately, neither their 
exposures nor the severity of their symptoms in 1991 are clear from the report. 
In a study by Nielsen et al. (34) a group of 43 workers were examined for 
immunologic markers for MTHPA exposure. Ten workers with work-related 
health problems and MTHPA-specific IgE had significantly higher levels of 
tryptase in nasal lavage fluid than 19 non-sensitized workers with work-related 
nasal symptoms, and also had significantly higher levels of eosinophilic cationic 
protein (ECP) in serum than an unexposed control group.  
HHPA, MHHPA and MTHPA. In a prospective study made in three factories 
(49), the relation between exposure and induction of IgE antibodies was followed 
in 163 previously unexposed persons (66 women, 97 men). The observation time 
was 1 to 105 (average 32) months. Air levels of organic acid anhydrides (MTHPA, 
HHPA and MHHPA) in the three factories were measured annually with personal 
or stationary monitors for 9, 4 and 9 years respectively. In all 748 samples were 
taken, representing a total sampling time of about 2000 hours. The subjects’ 
average exposure to HHPA and MHHPA, or to MTHPA, was 15.4 (<1 – 189) 
µg/m3. Specific IgE antibodies were identified in 21 of them (13%), and the 
average induction time was 8.8 (range 1 – 35) months. The incidence of sen-
sitization was 4.92 cases per 100 person-years of exposure. The proportion of 
sensitized subjects increased with increasing exposure: 6% at 0 – 5 µg/m3, 10%  
at >5 – 10 µg/m3, 15% at >10 – 15 µg/m3 and 25% at >15 µg/m3 (estimated from 
Figure 1 in Reference 49), which in number of persons corresponds to 2 of 34,  
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8 of 77, 3 of 20 and 8 of 32 (personal communication, Hans Welinder, Division  
of Occupational and Environmental Medicine, Lund University, Sweden). No 
correlation between sensitization and peak exposure levels was seen in this study 
(49). Although the study contains numerous monitoring measurements, exposure 
peaks are still a possibility. 
In the same prospective study, symptom development was followed in 146 new 
employees (62 women, 84 men) for up to 8.5 years (36). Air levels of organic acid 
anhydrides were measured annually (see above) (49). Average exposures were in 
the range 6 – 39 µg/m3. The incidences of work-related symptoms per 100 person-
years of exposure were 9.1 for eyes, 6.4 for nose, 4.6 for throat and 3.1 for lower 
respiratory tract. The conclusion drawn in this study is that exposure to organic 
acid anhydrides is frequently associated with dose-related symptoms involving 
eyes and respiratory tract (36). The authors report that symptoms also appeared  
at average exposures below 10 µg/m3, but present no statistical analysis. 
TCPA. Occupational asthma caused by TCPA has been verified by inhalation 
provocation. In several companies and several studies, workers have shown both 
immediate and late reactions. Positive reactions have been obtained in prick tests 
and RAST (radioallergosorbent tests) with TCPA-HSA conjugate. Symptoms and 
bronchial hyperreactivity persisted during the entire 12 years of a follow-up study 
made after exposure was ended by factory closure (4). 
In a Canadian cross-sectional study of 52 workers in a factory where they had 
been exposed to TCPA for only two years, 35% had occupational asthma and 31% 
(15 of 49) had specific IgE antibodies. Air samples were taken with personal and 
stationary monitors (total 15 samples); average TCPA exposures were in the range 
210 – 390 µg/m3. There was no correlation between occurrence of specific IgE 
antibodies and reported work-related respiratory symptoms or FEV1 reduction 
during a shift. After exposure had been reduced to <110 µg/m3 the symptoms 
became less severe and there were no new cases of asthma or sensitization, but  
the authors point out that the follow-up time (4 months) was brief and there were 
only a few subjects (27). 
THPA. No information on health effects caused by occupational exposure to 
THPA was found in the literature. 
Animal data 
MA and TMA have been shown to be extremely irritating to the eyes of rabbits 
(19). In an inhalation study, groups of rats, hamsters and monkeys were exposed 
to MA in concentrations of 0, 1000, 3000 or 10,000 µg/m3 6 hours/day, 5 
days/week for 6 months. Indications of irritation in eyes and nose were seen  
in all species at all exposure levels and were dose-related. Histopathological 
examinations revealed reversible inflammatory changes in the noses of all species 
(42). Lung function examination of the monkeys revealed no effects on lung 
function. Inhalation provocation with TMA of Brown Norway rats not previously 
sensitized had an effect on breathing pattern typical of irritation, and quite 
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different from the pattern seen in TMA-sensitized animals (1, 2). The changes 
were regarded as effects on the lower rather than the upper respiratory tract.  
The lowest concentration producing an effect was 14,000 µg/m3. Similar  
reactions have been reported in guinea pigs (20). 
 
Respiratory sensitization 
Animals have been sensitized to PA by both inhalation and subcutaneous injection 
of the substance. Animals have been sensitized to TMA by inhalation, intradermal 
injection of TMA in oil, and skin exposure to TMA in powder form (19). Dry 
TMA powder applied to the skin of Brown Norway rats four times in 21 days 
induced TMA-specific IgE antibodies. On provocation (35 days after the initial 
treatment) by inhalation of a TMA aerosol in concentrations of 200 to 40,000 
µg/m3, 1000 µg/m3 yielded an immediate allergic reaction in the form of increased 
airway resistance. Levels of 5000 and 40,000 µg/m3 yielded both immediate and 
late reactions (62). Changes in the respiratory passages of Brown Norway rats 
after inhalation of TMA were also studied by Zhang et al. (63). The rats were 
exposed to aerosols of 40, 400, 4000 or 40,000 µg/m3 for 10 minutes, once a  
week for 10 weeks, and then challenged with 40,000 µg/m3. In the rats in the two 
highest exposure groups, the treatments resulted in development of specific IgE 
antibodies and both early and late allergic reactions. The reactions were strongest 
in the rats previously exposed to 40,000 µg/m3 (63). Rats exposed by inhalation to 
TMA concentrations in the range 30 – 300 µg/m3 had pulmonary hemorrhages and 
specific antibodies, whereas a level of 10 µg/m3 had no apparent effect (21, 57). 
Provocation of guinea pigs sensitized by intradermal injection of free HHPA or 
MTHPA resulted in both airway obstruction and plasma extravasation, and the 
severity of the reactions correlated to the levels of specific IgG1 antibodies in 
serum (60). 
After guinea pigs had been sensitized by intradermal administration of 
equimolar amounts (0.3 M in 0.1 ml) of various organic acid anhydrides, IgG1 
titers were measured (48). The result yielded the following ranking (highest titer 
first): MTHPA > PA = MA > TMA = HHPA = MHHPA > THPA. A similar study 
(61) was made of IgE antibody formation in Brown Norway rats (0.2 M in 0.1 ml), 
and yielded the following ranking (highest titer first): PA > TMA = HHPA = 
MHHPA > MA = THPA = MTHPA. The authors suggested that titers of IgG1  
and IgE antibodies might be used as a measure of sensitizing potential. 
To summarize the animal experiments, after the animals have been sensitized, 
antibodies can be demonstrated against the anhydride as well as the new antigenic 
determinants in anhydride-modified albumin. IgG antibodies have usually been 
found, but in Brown Norway rats IgE antibodies have also been identified. 
Provocation with either free anhydride or the corresponding albumin conjugate  
is followed by immediate reactions in airways, which have been registered with 
plethysmography. Dose-response relationships have been observed: higher 
exposure leads to more antibody formation and more severe toxic reactions in the 
form of higher bronchial reactivity, higher vascular extravasation into airways, and 
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infiltration of eosinophilic granulocytes into the lungs. Hemorrhagic foci in lungs 
have been observed after exposure to TMA. Good correlations between exposure, 
antibody levels and lung damage exist here also. Caution should be used in 
extrapolating results from animal experiments to humans, since tests can produce 
different results in different sorts of animals. For example, different rat strains 
have very different reactions with regard to allergen-specific IgE. In addition, 
some of these studies can be difficult to reproduce because conditions, including 
those under which animals are kept, vary from lab to lab and may affect results.  
The animal studies reviewed here confirm the findings of the epidemiologic 
studies, but have been conducted at exposures too high to provide any information 
about LOELs (Lowest Observed Effect Levels).  
Mutagenicity, carcinogenicity, effects on reproduction 
Ames’ tests with PA and TCPA revealed no mutagenic activity. These substances 
had no effect on chromosome aberrations or sister chromatid exchange in either 
hamster ovary (CHO) cells or rat liver cells. A study with 10 mM PA, however, 
reports an increase of chromosome aberrations in CHO cells (19). 
The International Agency for Research on Cancer (IARC) has not published  
a carcinogenicity classification for any of the organic acid anhydrides reviewed  
in this document. 
Teratogenicity with exposure to PA has been studied in mice. No effects could 
be observed at doses that were not toxic to the mothers. Nor has MA shown any 
reproductive or teratogenic effects in animal studies (41). 
Dose-effect/dose-response relationships 
Dose-effect/dose-response relationships observed in humans and animals are 
summarized in Tables 2 and 3. The human studies were made in industries where 
several other chemical substances were also in use, which makes it difficult to 
differentiate, for example, the irritative effects of organic acid anhydrides from 
those of other substances. The sensitization, however, is specific. The data 
indicate that organic acid anhydrides are potent sensitizers. 
Acute effects observed in experimental exposures of both animals and humans 
are irritation of mucous membranes and skin, especially with exposure to the 
substances in powder form. An MA level of 1000 µg/m3 has caused eye irritation  
in animals (42). Data on humans are extremely limited. 
Skin exposure or intradermal injection of free or protein-bound organic acid 
anhydride results in dose-related immunization (formation of specific antibodies) 
in laboratory animals. Sensitized animals also show dose-dependent reactions  
to provocation (40, 60). For most of these organic acid anhydrides, it has been 
shown in animal studies that they are sensitizing and initiate development of IgE 
antibodies. This has also been observed in humans, for all the anhydrides reviewed 
here except THPA. 
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Lung hemorrhages and antibody development have been observed in rats after  
2 weeks of exposure to 30 µg/m3 TMA (Table 3) (21, 57). 
In the opinion of the Criteria Group, the formation of IgE antibodies specific for 
organic acid anhydrides can be regarded as a critical effect. This is based on the 
high probability that sensitized persons will develop health problems if exposure 
is continued. A similar stand has been taken by a Dutch expert group (13). 
Available data on human exposures has obvious gaps, and come almost entirely 
from cross-sectional studies. Another problem in determining the effects of 
specific organic acid anhydrides is the prevalence of mixed exposures. Further, 
there are no data on MA and THPA. One exposure factor of importance for dose-
effect/dose response relationships can be whether the substance is in gas or 
particle form. 
The correlations shown in Table 2 between exposure and effect apply to 
exposure averages. The correlations, grouped by substance and occurrence,  
are further described below. 
PA and MA. In a cross-sectional study of workers exposed to PA, those with an 
average exposure of 400 µg/m3 were likely to have work-related conjunctivitis 
(46%), rhinitis (40%) or asthma (14%). In the group with exposures below 100 
µg/m3 there were no cases of asthma, but 20% had conjunctivitis and/or rhinitis 
(31). In another study of 285 workers exposed to PA and MA there were 4 
sensitized subjects with average exposure levels of 9 – 62 µg/m3 (PA) and 2 – 3 
µg/m3 (MA) (3). There was also a low level of TMA. The study does not state 
which anhydrides caused the sensitization. 
TMA. In a cohort of workers exposed to TMA, the prevalence of sensitization and 
work-related symptoms increased with exposure. Positive prick tests and work-
related respiratory symptoms were significantly more frequent among workers 
exposed to levels above 10 µg/m3 than among those with lower exposure (3).  
At higher levels (1700 – 3600 µg/m3), 3 of 9 exposed workers developed asthma 
(23). In a cross-sectional study by Zeiss et al. (59), 2 of 8 persons in the highest 
exposure group (0.54 – 6500 µg/m3, geometric mean 170 µg/m3) had TMA-
specific IgE antibodies. 
HHPA and MHHPA. These two substances are sensitizing at low exposure 
levels. In a group (n = 95) exposed to average levels up to 140 µg/m3, 24%  
had specific IgE antibodies (47). Examinations were given to 154 workers in a 
company using HHPA and MHHPA as hardeners in epoxy plastics (35). Air levels 
of organic acid anhydrides were relatively low: <1 – 94 µg/m3 for HHPA and <3 –
77 µg/m3 for MHHPA. IgE antibodies specific for one or both of the anhydrides 
were identified in 22% of the subjects. Work-related symptoms were more 
frequent among the exposed workers than in 57 matched controls (eyes, 23% vs. 
14%; nose, 28% vs. 16%; nosebleeds, 8% vs. 0%; lower respiratory tract, 10% vs. 
4%). The workers were divided into three exposure categories based on current 
exposures (HHPA + MHHPA): <10, 10 – 50, and >50 µg/m3. There was a sig-
nificant correlation between exposure and symptoms involving the eyes, nose  
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and lower respiratory tract. Even in the lowest exposure group there was a 
significantly higher proportion of subjects with specific IgE antibodies (13% 
HHPA, 15% MHHPA), although the prevalence of symptoms was not 
significantly elevated. 
MTHPA. In a Japanese study, in a factory making condensers where average 
exposure was 5 µg/m3 (range 1 – 22 µg/m3) there was some sensitization, but it 
may have been a result of earlier high exposures. The prevalence of work-related 
symptoms involving the eyes and nose, among both sensitized and unsensitized 
subjects, was higher in another factory with higher average exposure, and in both 
factories was higher for sensitized subjects than for those not sensitized (53). 
Exposure levels in a German study were <0.5 –36 µg/m3, and of 5 persons with 
clinically relevant sensitization, all had fewer and 4 of 5 had less severe symptoms 
after previously higher exposures had been reduced to these levels (8, 9). This 
observation is in some contrast to those made by Nielsen et al. (33). Among 
workers exposed to 5 – 20 µg/m3 56% had symptoms involving eyes and upper 
respiratory tract, 9% had asthma, and 16% had specific antibodies. In a group with 
higher exposure (20 – 150 µg/m3) 65% had eye and upper respiratory symptoms, 
11% had asthma, and 22% had specific antibodies (33, 46). 
HHPA, MHHPA and MTHPA. In a prospective study the relation between 
exposure and induction of IgE antibodies was examined in 163 previously 
unexposed workers (49). Observation time was 1 to 105 (mean 32) months. 
Average exposure to organic acid anhydrides was 15.4 (<1 – 189) µg/m3. The 
sensitization incidence was 4.92 cases per 100 person-years of exposure. The 
proportion of sensitized subjects increased with increasing exposure: 6% at 0 – 5 
µg/m3, 10% at >5 – 10 µg/m3, 15% at >10 – 15 µg/m3, and 25% at >15 µg/m3 
(49). In the same prospective study, symptom development was followed in  
146 new employees (62 women, 84 men) for up to 8.5 years (36). The air 
concentrations of organic acid anhydrides (MTHPA, HHPA and MHHPA 
combined) were measured yearly. Exposure averages ranged from 6 to 39 µg/m3. 
The incidences of work-related symptoms per 100 person-years of exposure were 
9.1 for eyes; 6.4 for nose; 4.6 for throat; and 3.1 for lower respiratory tract. The 
authors report that symptoms also appeared at average exposures below 10 µg/m3, 
but they present no statistical analysis. 
TCPA. In a Canadian cross-sectional study of 52 workers in a factory where 
TCPA had been in use for only two years, 35% of the workers had occupational 
asthma and 31% (15 of 49) had TCPA-specific IgE antibodies. Exposure averages 
were in the range 210 – 390 µg/m3. After exposure had been reduced to <110 
µg/m3 the symptoms became less severe and no new cases of asthma or sen-
sitization occurred (27). The observation period was short, however, and there 
were few subjects. 
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Conclusions 
The critical effect of occupational exposure to organic acid anhydrides is sen-
sitization. Sensitization has been documented at average exposure levels around  
5 µg/m3. It can lead to allergic problems such as asthma and rhinitis. With present 
knowledge it is not possible to differentiate the various organic acid anhydrides 
regarding potency or the threshold for sensitization. 
Experimental animals have developed respiratory tract sensitization after 
dermal exposure. The amount of skin uptake, however, can not be estimated. 
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Table 2. Dose-effect/dose-response relationships noted in workers exposed to organic 
acid anhydrides via inhalation. 
 
Exposure in  
µg/m3 (range) 
Number 
exposed 
Average years of 
exposure (range) 
Effects Ref. 
  
MA/PA/TMA*     
<3 (MA) 
9 – 62 (PA) 
0.5 – 0.9 (TMA) 
285  A total of 4 cases (1.4%) with 
specific IgE. 
3 
     
PA     
<100 25 11.9 
(0.3 – 40) 
12% specific IgE 
20% conjunctivitis 
20% rhinitis 
0% asthma 
31 
400 35 13.3 
(0 – 43) 
3% specific IgE 
46% conjunctivitis 
40% rhinitis 
14% asthma 
 
     
TMA     
<10 
10 – 40 
>40 
63 
36 
8 
 1 prick test positive 
5 prick test positive 
2 prick test positive 
At exposures above 10 µg/m3 the 
proportions of workers with work-
related respiratory symptoms and 
positive prick tests for TMA-specific 
antibodies were significantly higher 
than at lower exposures. 
3 
1700 – 3600 9  11% specific IgE 
44% symptoms of irritation 
33% asthma 
23 
170 
(0.54 – 6500) 
8  2 had TMA-specific IgE antibodies 59 
     
HHPA/MHHPA*     
30  
(2 – 62) 
32 9 
(0.2 – 21) 
8 (25%) had specific IgE; 5 of these 
had work-related eye and nasal 
symptoms. 
55 
about 35 
(2 – 470) 
 
95 7.0 
(0.1 – 25) 
23 (24%) subjects with specific IgE. 47 
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Table 2. Cont. 
 
Exposure in  
µg/m3 (range) 
Number 
exposed 
Average years of 
exposure (range) 
Effects Ref. 
  
0 (controls) 57 5.0 0% specific IgE 
14% eye symptoms 
16% nasal symptoms 
4% lower respiratory tract symptoms 
35 
<10 53 6.0 15% specific IgE (MHHPA)  
13% specific IgE (HHPA) 
15% eye symptoms 
30% nasal symptoms 
8% lower respiratory tract symptoms 
 
10 – 50 72 3.5 26% specific IgE (MHHPA)  
26% specific IgE (HHPA) 
25% eye symptoms 
26% nasal symptoms 
14% lower respiratory tract 
symptoms 
 
>50 29 5.5 17% specific IgE (MHHPA),  
21% specific IgE (HHPA) 
34% eye symptoms 
28% nasal symptoms 
17% lower respiratory tract 
symptoms 
 
     
MTHPA     
5 
(1 – 22) 
58 12.4 
(1.3 – 20) 
66% specific IgE 
26% eye symptoms 
34% nasal symptoms 
0% asthma 
53 
26 – 64 
(7 – 421) 
37 5.6 
(0.2 – 13) 
65% specific IgE 
57% eye symptoms 
70% nasal symptoms 
0% asthma 
 
<0.5 – 36 84  Of 5 persons with clinically relevant 
sensitization, all showed fewer and 4 
of 5 milder symptoms after 
previously higher air levels had been 
reduced. 
8, 9 
0 (controls) 33  0% specific IgE 
9% eye/upper respiratory tract 
symptoms 
0% asthma 
33 
5 – 20 70  16% specific IgE 
56% eye/upper respiratory tract 
symptoms 
9% asthma 
 
20 – 150 55 2.0 
(0.1 – 6.0) 
22% specific IgE 
65% eye/upper respiratory tract 
symptoms 
11% asthma 
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Table 2. Cont. 
 
Exposure in  
µg/m3 (range) 
Number 
exposed 
Average years of 
exposure (range) 
Effects  Ref. 
  
HHPA/MHHPA/ 
MTHPA** 
    
≤5 
>5 – 10 
>10 – 15 
>15 
163 
(total) 
0.7 
(0.1 – 2.9) 
6% specific IgE 
10% specific IgE 
15% specific IgE 
25% specific IgE 
49 
6 – 39 146 ≤9.0 Incidences of work-related symptoms per 
100 person-years of exposure: 9.1, eyes; 6.4, 
nose; 4.6, throat; 3.1 lower respiratory tract. 
36 
     
TCPA     
210 – 390 52 2.5 
(0.1 – 8.1) 
35% asthma 
31% specific IgE (15/49) 
27 
<110 5 <0.33 0% asthma 
0% specific IgE 
 
 
* mixed exposures 
** exposure to HHPA and MHHPA, or to MTHPA 
 
 
Table 3. Dose-effect/dose-response relationships observed in laboratory animals after 
inhalation exposure to organic acid anhydrides. 
 
Exposure 
(µg/m3) 
Number of 
animals 
Exposure Effects Ref. 
 
MA     
1000   Symptoms of irritation in eyes and 
upper respiratory tract. 
42 
TMA     
10 60 6 hrs/day,  
5 days/week, 
2 weeks 
Limited effects on rats. 21, 
57 
30 
 
60 6 hrs/day, 
5 days/week, 
2 weeks 
Antibody production, hemorrhages in 
lungs. 
 
100 
 
60 6 hrs/day, 
5 days/week, 
2 weeks 
Maximum antibody production. 
(no higher at 300 µg/m3) 
 
40 4 10 min/week 
10 weeks 
0% positive IgE 63 
400 4 10 min/week 
10 weeks 
25% positive IgE  
4000 8 10 min/week 
10 weeks 
100% positive IgE, 100% early and late 
asthmatic reactions on provocation. 
 
40,000 8 10 min/week 
10 weeks 
100% positive IgE, 100% early and late 
asthmatic reactions on provocation. 
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Summary 
 
Montelius J (ed). Swedish Criteria Group for Occupational Standards. Scientific 
Basis for Swedish Occupational Standards. XXIX. Arbete och Hälsa 
2009;43(4):1-74. University of Gothenburg, Sweden. 
 
Critical review and evaluation of those scientific data which are relevant as a 
background for discussion of Swedish occupational exposure limits. This volume 
consists of the consensus reports given by the Criteria Group at the Swedish Work 
Environment Authority from October, 2007 through June, 2008. 
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Sammanfattning 
 
Montelius J (ed). Kriteriegruppen för hygieniska gränsvärden. Vetenskapligt 
underlag för hygieniska gränsvärden. XXIX. Arbete och Hälsa 2009;43;(4):1-74. 
Göteborgs Universitet. 
 
Sammanställningar baserade på kritisk genomgång och värdering av de 
vetenskapliga fakta, vilka är relevanta som underlag för fastställande av hygieniskt 
gränsvärde. Volymen omfattar de underlag som avgivits från Kriteriegruppen för 
hygieniska gränsvärden under perioden oktober 2007 – juni 2008. 
 
Nyckelord; Etylenglykoletyleter, Etylenglykoletyleteracetat, Hygieniskt 
gränsvärde, Kreosot, Organiska syraanhydrider, Riskvärdering, 
Toxikologi, Vetenskapligt underlag. 
 
 
En svensk version av dessa vetenskapliga underlag finns publicerad i Arbete och 
Hälsa 2009;43(1):1-73. 
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APPENDIX 
 
Consensus reports in this and previous volumes 
 
 
Substance Consensus  
date 
Published in  
Arbete och Hälsa 
year;volume(No) 
No. in series  
of Consensus 
Reports 
 
Acetaldehyde February 17, 1987 1987;39 VIII 
Acetamide December 11, 1991 1992;47 XIII 
Acetic acid June15, 1988 1988;32 IX 
Acetone October 20, 1987 1988;32 IX 
Acetonitrile September 12, 1989 1991;8 XI 
Acrylamide April 17, 1991 1992;6 XII 
Acrylates December 9, 1984 1985;32 VI 
Acrylonitrile April 28, 1987 1987;39 VIII 
Aliphatic amines August 25, 1982 1983;36 IV 
Aliphatic hydrocarbons, C10-C15 June 1, 1983 1983;36 IV 
Aliphatic monoketons September 5, 1990 1992;6 XII 
Allyl alcohol September 9, 1986 1987;39 VIII 
Allylamine August 25, 1982 1983;36 IV 
Allyl chloride June 6,  1989 1989;32 X 
Aluminum April 21, 1982 1982;24 III 
      revised September 14, 1994 1995;19 XVI 
Aluminum trifluoride September 15, 2004 2005;17 XXVI 
p-Aminoazobenzene February 29, 1980 1981;21 I 
Ammonia April 28, 1987 1987;39 VIII 
      revised October 24, 2005 2006;11 XXVII 
Ammonium fluoride September 15, 2004 2005;17 XXVI 
Amylacetate March 23, 1983 1983;36 IV 
      revised June 14, 2000 2000;22 XXI 
Aniline October 26, 1988 1989;32 X 
Anthraquinone November 26, 1987 1988;32 IX 
Antimony + compounds December 8, 1999 2000;22 XXI 
Arsenic, inorganic December 9, 1980 1982;9 II 
      revised February 15, 1984 1984;44 V 
Arsine October 20, 1987 1988;32 IX 
Asbestos October 21, 1981 1982;24 III 
    
Barium June 16, 1987 1987;39 VIII 
      revised January 26, 1994 1994;30 XV 
Benzene March 4, 1981 1982;9 II 
      revised February 24, 1988 1988;32 IX 
Benzoyl peroxide February 13, 1985 1985;32 VI 
Beryllium April 25, 1984 1984;44 V 
Borax October 6, 1982 1983;36 IV 
Boric acid October 6, 1982 1983;36 IV 
Boron Nitride January 27, 1993 1993;37 XIV 
Butadiene October 23, 1985 1986;35 VII 
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1-Butanol June 17, 1981 1982;24 III 
Butanols June 6, 1984 1984;44 V 
Butyl acetate June 6, 1984 1984;44 V 
Butyl acetates February 11, 1998 1998;25 XIX 
Butylamine August 25, 1982 1983;36 IV 
Butyl glycol October 6, 1982 1983;36 IV 
γ-Butyrolactone June 2, 2004 2005;7 XXV 
    
Cadmium January 18, 1980 1981;21 I 
      revised February 15, 1984 1984;44 V 
      revised May 13, 1992 1992;47 XIII 
      revised February 5, 2003 2003;16 XXIV 
Calcium fluorid September 15, 2004 2005;17 XXVI 
Calcium hydroxide February 24, 1999 1999;26 XX 
Calcium nitride January 27, 1993 1993;37 XIV 
Calcium oxide February 24, 1999 1999;26 XX 
Caprolactam October 31, 1989 1991;8 XI 
Carbon monoxide December 9, 1981 1982;24 III 
Cathecol September 4, 1991 1992;47 XIII 
Chlorine December 9, 1980 1982;9 II 
Chlorine dioxide December 9, 1980 1982;9 II 
Chlorobenzene September 16, 1992 1993;37 XIV 
      revised April 2, 2003 2003;16 XXIV 
o-Chlorobenzylidene malononitrile June 1, 1994 1994;30 XV 
Chlorocresol December 12, 1990 1992;6 XII 
Chlorodifluoromethane June 2, 1982 1982; 24 III 
Chlorophenols September 4, 1985 1986;35 VII 
Chloroprene April 16, 1986 1986;35 VII 
Chromium December 14, 1979 1981;21 I 
      revised May 26, 1993 1993;37 XIV 
      revised May 24, 2000 2000;22 XXI 
Chromium trioxide May 24, 2000 2000;22 XXI 
Coal dust September 9, 1986 1987;39 VIII 
Cobalt October 27, 1982 1983;36 IV 
Cobalt and cobalt compounds October 22, 2003 2005;7 XXV 
Copper October 21, 1981 1982;24  III 
Cotton dust February14, 1986 1986;35 VII 
Creosote October 26, 1988 1989;32 X 
      revised December 5, 2007 2009;43(4) XXIX 
Cresols February 11, 1998 1998;25 XIX 
Cumene June 2, 1982 1982;24 III 
Cyanamid September 30, 1998 1999;26 XX 
Cyanoacrylates March 5, 1997 1997;25 XVIII 
Cycloalkanes, C5-C15 April 25, 1984 1984;44 V 
Cyclohexanone March 10, 1982 1982;24 III 
      revised February 24, 1999 1999;26 XX 
Cyclohexanone peroxide February 13, 1985 1985;32 VI 
Cyclohexylamine February 7, 1990 1991;8 XI 
    
Desflurane May 27, 1998 1998;25 XIX 
Diacetone alcohol December 14, 1988 1989;32 X 
69 
Dichlorobenzenes February 11, 1998 1998;25 XIX 
1,2-Dibromo-3-chloropropane May 30, 1979 1981;21 I 
Dichlorodifluoromethane June 2, 1982 1982;24 III 
1,2-Dichloroethane February 29, 1980 1981;21 I 
Dichloromethane February 29, 1980 1981;21 I 
Dicumyl peroxide February 13, 1985 1985;32 VI 
Dicyclopentadiene March 23, 1994 1994;30 XV 
Diesel exhaust December 4, 2002 2003;16 XXIV 
Diethanolamine September 4, 1991 1992;47 XIII 
Diethylamine August 25, 1982 1983;36 IV 
2-Diethylaminoethanol January 25, 1995 1995;19 XVI 
Diethylene glycol September 16, 1992 1993;37 XIV 
Diethyleneglycol ethylether + acetate December 11, 1996 1997;25 XVIII 
Diethyleneglycol methylether + acetate March 13, 1996 1996;25 XVII 
Diethyleneglycol monobutylether January 25, 1995 1995;19 XVI 
Diethylenetriamine August 25, 1982 1983;36 IV 
      revised January 25, 1995 1995;19 XVI 
Diisocyanates April 8, 1981 1982;9 II 
      revised April 27, 1988 1988;32 IX 
      revised May 30, 2001 2001;20 XXII 
Diisopropylamine February 7, 1990 1991;8 XI 
N,N-Dimethylacetamide March 23, 1994 1994;30 XV 
Dimethyl adipate December 9, 1998 1999;26 XX 
Dimethylamine December 10, 1997 1998;25 XIX 
N,N-Dimethylaniline December 12, 1989 1991;8 XI 
Dimethyldisulfide September 9, 1986 1987;39 VIII 
Dimethylether September 14, 1994 1995;19 XVI 
Dimethylethylamine June 12, 1991 1992;6 XII 
Dimethylformamide March 23, 1983 1983;36 IV 
Dimethyl glutarate December 9, 1998 1999;26 XX 
Dimethylhydrazine January 27, 1993 1993;37 XIV 
Dimethyl succinate December 9, 1998 1999;26 XX 
Dimethylsulfide September 9, 1986 1987;39 VIII 
Dimethylsulfoxide, DMSO December 11, 1991 1992;47 XIII 
Dioxane August 25, 1982 1983;36 IV 
      revised March 4, 1992 1992;47 XIII 
Diphenylamine January 25, 1995 1995;19 XVI 
4,4'-Diphenylmethanediisocyanate (MDI) April 8, 1981 1982;9 II 
      revised May 30, 2001 2001;20 XXII 
Dipropylene glycol May 26, 1993 1993;37 XIV 
Dipropyleneglycol monomethylether December 12, 1990 1992;6 XII 
Disulfiram October 31, 1989 1991;8 XI 
    
Enzymes, industrial June 5, 1996 1996;25 XVII 
Ethanol May 30, 1990 1991;8 XI 
Ethanolamine September 4, 1991 1992;47 XIII 
Ethylacetate March 28, 1990 1991;8 XI 
Ethylamine August 25, 1982 1983;36 IV 
Ethylamylketone September 5, 1990 1992;6 XII 
Ethylbenzene December 16, 1986 1987;39 VIII 
Ethylchloride December 11, 1991 1992;47 XIII 
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Ethylene December 11, 1996 1997;25 XVIII 
Ethylene chloride February 29, 1980 1981;21 I 
Ethylene diamine August 25, 1982 1983;36 IV 
Ethylene glycol October 21, 1981 1982;24 III 
Ethylene glycol ethylether + acetate February 6 2009;43(4) XXIX 
Ethylene glycol methylether + acetate June 2, 1999 1999;26 XX 
Ethyleneglycol monoisopropylether November 16, 1994 1995;19 XVI 
Ethyleneglycol monopropylether + acetate September 15, 1993 1994;30 XV 
Ethylene oxide December 9, 1981 1982;24 III 
Ethylenethiourea September 27, 2000 2001;20 XXII 
Ethylether January 27, 1993 1993;37 XIV 
Ethylglycol October 6, 1982 1983;36 IV 
    
Ferbam September 12, 1989 1991;8 XI 
Ferric dimethyldithiocarbamate September 12, 1989 1991;8 XI 
Flour dust December 10, 1997 1998;25 XIX 
Fluorides September 15, 2004 2005;17 XXVI 
Formaldehyde June 30, 1979 1981;21 I 
      revised August 25, 1982 1983;36 IV 
Formamide December 12, 1989 1991;8 XI 
Formic acid June 15, 1988 1988;32 IX 
Furfural April 25, 1984 1984;44 V 
Furfuryl alcohol February 13, 1985 1985;32 VI 
    
Gallium + Gallium compounds January 25, 1995 1995;19 XVI 
Glutaraldehyde September 30, 1998 1999;26 XX 
Glycol ethers October 6, 1982 1983;36 IV 
Glyoxal September 13, 1996 1996;25 XVII 
Grain dust December 14, 1988 1989;32 X 
Graphite December 10, 1997 1998;25 XIX 
    
Halothane April 25, 1985 1985;32 VI 
2-Heptanone September 5, 1990 1992;6 XII 
3-Heptanone September 5, 1990 1992;6 XII 
Hexachloroethane September 15, 1993 1994;30 XV 
Hexamethylenediisocyanate (HDI) April 8, 1981 1982;9 II 
      revised May 30, 2001 2001;20 XXII 
Hexamethylenetetramine August 25, 1982 1983;36 IV 
n-Hexanal March 29, 2006 2006;11 XXVII 
n-Hexane January 27, 1982 1982;24 III 
2-Hexanone September 5, 1990 1992;6 XII 
Hexyleneglycol November 17, 1993 1994;30 XV 
Hydrazine May 13, 1992 1992;47 XIII 
Hydrogen bromide February 11, 1998 1998;25 XIX 
Hydrogen cyanide February 7, 2001 2001;20 XXII 
Hydrogen fluoride April 25, 1984 1984;44 V 
      revised September 15, 2004 2005;17 XXVI 
Hydrogen peroxide April 4, 1989 1989;32 X 
Hydrogen sulfide May 4, 1983 1983;36 IV 
Hydroquinone October 21, 1989 1991;8 XI 
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Indium March 23, 1994 1994;30 XV 
Industrial enzymes June 5, 1996 1996;25 XVII 
Isocyanic Acid (ICA) December 5, 2001 2002;19 XXIII 
Isophorone February 20, 1991 1992;6 XII 
Isopropanol December 9, 1981 1982;24 III 
Isopropylamine February 7, 1990 1991;8 XI 
Isopropylbenzene June 2, 1982 1982;24 III 
    
Lactates March 29, 1995 1995;19 XVI 
Lactate esters June 2, 1999 1999;26 XX 
Laughing gas June 7, 2006 2006;11 XXVII 
Lead, inorganic February 29, 1980 1981;21 I 
      revised September 5, 1990 1992;6 XII 
      revised December 8, 2004 2005;17 XXVI 
Lithium and lithium compounds June 4, 2003 2003;16 XXIV 
Lithium boron nitride January 27, 1993 1993;37 XIV 
Lithium nitride January 27, 1993 1993;37 XIV 
    
Maleic anhydride September 12, 1989 1991;8 XI 
Manganese February 15, 1983 1983;36 IV 
      revised April 17, 1991 1992;6 XII 
      revised June 4, 1997 1997;25 XVIII 
Man made mineral fibers March 4, 1981 1982;9 II 
      revised December 1, 1987 1988;32 IX 
Mercury, inorganic April 25, 1984 1984;44 V 
Mesityl oxide May 4, 1983 1983;36 IV 
Metal stearates, some September 15, 1993 1994;30 XV 
Methacrylates September 12, 1984 1985;32 VI 
Methanol April 25, 1985 1985;32 VI 
Methyl acetate March 28, 1990 1991;8 XI 
Methylamine August 25, 1982 1983;36 IV 
Methylamyl alcohol March 17, 1993 1993;37 XIV 
Methyl bromide April 27, 1988 1988;32 IX 
Methyl chloride March 4, 1992 1992;47 XIII 
Methyl chloroform March 4, 1981 1982;9 II 
4,4´-methylene-bis-(2-chloroaniline) February 4, 2004 2005;7 XXV 
Methylene chloride February 29, 1980 1981;21 I 
4,4'-Methylene dianiline June 16, 1987 1987;39 VIII 
      revised October 3, 2001 2002;19 XXIII 
Methyl ethyl ketone February 13, 1985 1985;32 VI 
Methyl ethyl ketone peroxide February 13, 1985 1985;32 VI 
Methyl formate December 12, 1989 1991;8 XI 
Methyl glycol October 6, 1982 1983;36 IV 
Methyl iodide June 30, 1979 1981;21 I 
Methylisoamylamine September 5, 1990 1992;6 XII 
Methylisoamylketone February 6, 2002 2002;19 XXIII 
Methylisocyanate (MIC) December 5, 2001 2002;19 XXIII 
Methyl mercaptane September 9, 1986 1987;39 VIII 
Methyl methacrylate March 17, 1993 1993;37 XIV 
Methyl pyrrolidone June 16, 1987 1987;39 VIII 
α-Methylstyrene November 1, 2000 2001;20 XXII 
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Methyl-t-butyl ether November 26, 1987 1988;32 IX 
      revised September 30, 1998 1999;26 XX 
Mixed solvents, neurotoxicity April 25, 1985 1985;32 VI 
MOCA February 4, 2004 2005;7 XXV 
Molybdenum October 27, 1982 1983;36 IV 
Monochloroacetic acid February 20, 1991 1992;6 XII 
Monochlorobenzene September 16, 1993 1993;37 XIV 
Monomethylhydrazine March 4, 1992 1992;47 XIII 
Mononitrotoluene February 20, 1991 1992;6 XII 
Monoterpenes February 17, 1987 1987;39 VIII 
Morpholine December 8, 1982 1983;36 IV 
      revised June 5, 1996 1996;25 XVII 
    
Naphthalene May 27, 1998 1998;25 XIX 
Natural crystallinic fibers, except asbestos June 12, 1991 1992;6 XII 
Nickel April 21, 1982 1982;24 III 
Nicotine June 2, 2004 2005;7 XXV 
Nitric oxide December 11, 1985 1986;35 VII 
      revised June 13, 2007 2008;42(6) XXVIII 
Nitroethane April 4, 1989 1989;32 X 
Nitrogen dioxide December 11, 1985 1986;35 VII 
      revised September 12, 2007 2008;42(6) XXVIII 
Nitrogen oxides December 11, 1985 1986;35 VII 
Nitroglycerin February 13, 1985 1985;32 VI 
Nitroglycol February 13, 1985 1985;32 VI 
Nitromethane January 6, 1989 1989;32 X 
Nitropropane October 28, 1986 1987;39 VIII 
2-Nitropropane March 29, 1995 1995;19 XVI 
Nitroso compounds December 12, 1990 1992;6 XII 
Nitrosomorpholine December 8, 1982 1983;36 IV 
Nitrotoluene February 20, 1991 1992;6 XII 
Nitrous oxide December 9, 1981 1982;24 III 
      revised June 7, 2006 2006;11 XXVII 
    
Oil mist April 8, 1981 1982;9 II 
Organic acid anhydrides, some September 12, 1989 1991;8 XI 
      revised June 4, 2008 2009;43(4) XXIX 
Oxalic acid February 24, 1988 1988;32 IX 
Ozone April 28, 1987 1987;39 VIII 
      revised February 7, 2007 2008;42(6) XXVIII 
    
Paper dust February 7, 1990 1991;8 XI 
Penicillins November 23, 2005 2006;11 XXVII 
Pentaerythritol November 16, 1994 1995;19 XVI 
1,1,1,2,2-Pentafluoroethane February 24, 1999 1999;26 XX 
Pentyl acetate June 14, 2000 2000;22 XXI 
Peroxides, organic February 13, 1985 1985;32 VI 
Phenol February 13, 1985 1985;32 VI 
Phosphorous chlorides September 30, 1998 1999;26 XX 
Phosphorous oxides February 11, 1998 1998;25 XIX 
Phthalates December 8, 1982 1983;36 IV 
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Phthalic anhydride September 12, 1989 1991;8 XI 
Piperazine September 12, 1984 1985;32 VI 
Plastic dusts December 16, 1986 1987;39 VIII 
Platinum June 4, 1997 1997;25 XVIII 
Polyaromatic hydrocarbons February 15, 1984 1984;44 V 
Polyisocyanates April 27, 1988 1988;32 IX 
Potassium aluminium fluoride June 4, 1997 1997;25 XVIII 
Potassium cyanide February 7, 2001 2001;20 XXII 
Potassium dichromate May 24, 2000 2000;22 XXI 
Potassium Fluoride September 15, 2004 2005;17 XXVI 
Potassium hydroxide Marsh 15, 2000 2000;22 XXI 
2-Propanol December 9, 1981 1982;24 III 
Propene September 13, 1996 1996;25 XVII 
Propionic acid November 26, 1987 1988;32 IX 
Propylacetate September 14, 1994 1995;19 XVI 
Propylene glycol June 6, 1984 1984;44 V 
Propylene glycol-1,2-dinitrate May 4, 1983 1983;36 IV 
Propylene glycol monomethylether October 28, 1986 1987;39 VIII 
Propylene oxide June 11, 1986 1986;35 VII 
Pyridine May 13, 1992 1992;47 XIII 
    
Quartz March 13, 1996 1996;25 XVII 
    
Resorcinol September 4, 1991 1992;47 XIII 
    
Selenium December 11, 1985 1986;35 VII 
      revised February 22, 1993 1993;37 XIV 
Sevoflurane May 27, 1998 1998;25 XIX 
Silica March 13, 1996 1996;25 XVII 
Silver October 28, 1986 1987;39 VIII 
Sodium cyanide February 7, 2001 2001;20 XXII 
Sodium Fluoride September 15, 2004 2005;17 XXVI 
Sodium hydroxide August 24, 2000 2000;22 XXI 
Stearates, metallic, some September 15, 1993 1994;30 XV 
Stearates, non-metallic, some November 17, 1993 1994;30 XV 
Strontium January 26, 1994 1994;30 XV 
Styrene February 29, 1980 1981;21 I 
      revised October 31, 1989 1991;8 XI 
Sulfur dioxide April 25, 1985 1985;32 VI 
Sulfur fluorides March 28, 1990 1991;8 XI 
Synthetic inorganic fibers March 4, 1981 1982;9 II 
      revised December 1, 1987 1988;32 IX 
      revised December 3, 2003 2005;7 XXV 
Synthetic organic and inorganic fibers May 30, 1990 1991;8 XI 
    
Talc dust June 12, 1991 1992;6 XII 
Terpenes, mono- February 17, 1987 1987;39 VIII 
Tetrabromoethane May 30, 1990 1991;8 XI 
Tetrachloroethane June 4, 1997 1997;25 XVIII 
Tetrachloroethylene February 29, 1980 1981;21 I 
1,1,1,2-Tetrafluoroethane March 29, 1995 1995;19 XVI 
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Tetrahydrofuran October 31, 1989 1991;8 XI 
Tetranitromethane April 4, 1989 1989;32 X 
Thioglycolic acid June 1, 1994 1994;30 XV 
Thiourea December 1, 1987 1988;32 IX 
      revised June 2, 1999 1999;26 XX 
Thiram October 31, 1989 1991;8 XI 
Thiurams, some October 31, 1989 1991;8 XI 
Tin and inorganic tin compounds October 22, 2003 2005;7 XXV 
Titanium dioxide February 21, 1989 1989;32 X 
Toluene February 29, 1980 1981;21 I 
      revised February 6, 2002 2002;19 XXIII 
Toluene-2,4-diamine November 1, 2000 2001;20 XXII 
Toluene-2,6-diamine November 1, 2000 2001;20 XXII 
Toluene-2,4-diisocyanate April 8,  1981 1982;9 II 
      revised May 30, 2001 2001;20 XXII 
Toluene-2,6-diisocyanate April 8, 1981 1982;9 II 
      revised May 30, 2001 2001;20 XXII 
1,1,1-Trifluoroethane February 24, 1999 1999;26 XX 
Trichlorobenzene September 16, 1993 1993;37 XIV 
1,1,1-Trichloroethane March 4, 1981 1982;9 II 
Trichloroethylene December 14, 1979 1981;21 I 
Trichlorofluoromethane June 2, 1982 1982;24 III 
1,1,2-Trichloro-1,2,2-trifluoroethane June 2, 1982 1982;24 III 
Triethanolamine August 25, 1982 1983;36 IV 
      revised October 23, 2002 2003;16 XXIV 
Triethylamine December 5, 1984 1985;32 VI 
Trimellitic anhydride September 12, 1989 1991;8 XI 
Trimethylolpropane November 16, 1994 1995;19 XVI 
Trinitrotoluene April 17, 1991 1992;6 XII 
    
Vanadium March 15, 1983 1983;36 IV 
Vinyl acetate June 6, 1989 1989;32 X 
Vinyl toluene December 12, 1990 1992;6 XII 
    
White spirit December 16, 1986 1987;39 VIII 
      revised November 13, 2006 2008;42(6) XXVIII 
Wood dust June 17, 1981 1982;9 II 
      revised June 25, 2000 2000;22 XXI 
    
Xylene February 29, 1980 1981;21 I 
      revised September 14, 2005 2005;17 XXVI 
    
Zinc April 21, 1982 1982;24 III 
Zinc chromate May 24, 2000 2000;22 XXI 
Zinc dimethyl dithiocarbamate September 12, 1989 1991;8 XI 
Ziram September 12, 1989 1991;8 XI 
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